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VOORWOORD 
 
 
Dit proefschrift is het resultaat van een vierjarige inspanning; een inspanning die 
nooit tot dit proefschrift zou geleid hebben zonder de hulp van velen. 
 
Eerst en vooral wil ik mijn promotoren bedanken. Bij Prof. Dr. M. De Vos kon 
ik enerzijds op gelijk welk moment te rade gaan. Onoverkomelijke problemen 
werden door haar meestal herleid tot nieuwe inzichten. Anderzijds werkte haar 
ambitie aanstekelijk op momenten waar mijn ambitie iets minder was. Prof. Dr. 
G. Leroux-Roels bedank ik voor het steeds aandachtig bekijken van resultaten, 
mij terechtwijzend waar ik iets minder kritisch was geweest.  
 
Een bijzonder dankwoord gaat uit naar Prof. Dr. J. Delanghe, lid van mijn 
begeleidingscommissie. Zonder zijn fenomenale kennis van het ‘haptoglobine-
gebeuren’ en het daaraan gekoppelde enthousiasme, had ik dit proefschrift nooit 
kunnen schrijven. De gesprekken, waar mijn rol vooral een luisterende was, 
rond de geografische en historische impact van het haptoglobine fenotype waren 
een uitermate aangename en leerrijke verademing. 
 
Voor de honderden bepalingen van het haptoglobine fenotype, bedank ik van 
harte Mevr. L. Claeys. Haar uitleg over deze techniek blijft ook voor een 
clinicus verstaanbaar.  
 
De hulp die ik kreeg van Dhr. H. Verdievel voor de NTBI bepalingen is niet te 
beschrijven. Het oppuntstellen van een nieuwe, uitermate arbeidsintensieve 
techniek, gebeurde vlot en correct.  
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Mevr. N. Van Damme en Dr. H. Peeters wil ik bedanken voor de CD163 
bepalingen. Ik realiseer mij dat deze bepalingen vaak op ongelegen momenten 
dienden te gebeuren. De discussies rond de flowcytometrietechniek waren voor 
mij verhelderend.  
 
Dr. M. Langlois bedank ik voor het aanbrengen van extra sera van patiënten met 
erfelijke hemochromatose. 
 
Dankzij de bereidheid van de leden van het steeringcomité van de BASL 
(Belgian Association of the Study of the Liver), kon ik toegang krijgen tot 
verschillende dossiers van patiënten met erfelijke hemochromatose. 
 
Mijn collega’s van de polikliniek gastro-enterologie, Dr. I. Colle, Prof. Dr. D. 
De Looze en Prof. Dr. M. Peeters bedank ik voor hun geduld en bereidheid tot 
het overnemen van klinisch werk op momenten dat dit proefschrift mijn 
aanwezigheid in de kliniek onmogelijk maakte. 
 
Het formaat van dit proefschrift zou er totaal anders uitgezien hebben zonder de 
hulp van Mevr. A. Verbist, die de lay-out van dit boek verzorgde. Zij schiep 
orde in de chaos. 
 
Dhr. A. Dehaene van Roche bedank ik voor de logistieke steun bij het drukwerk. 
 
Een heel bijzonder dankwoord gaat uit naar mijn ouders. Zonder hen was niets 
mogelijk. Hun liefdevolle interesse gedurende de periode van dit proefschrift 
was steeds een extra stimulans. 
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En last, but not least, wil ik mijn echtgenote, Nancy, bedanken. Heel veel van 
haar vrije tijd moest zij mijn aanwezigheid ontberen. Toch hielp zij mij veel 
zaken te relativeren. Zij vatte dit samen met de volgende tekst. 
 
Neem de tijd om te werken, 
Dat is de prijs van het succes. 
 
Neem de tijd om te denken, 
Dat is de bron van de macht. 
 
Neem de tijd om te spelen, 
Dat is het geheim van de eeuwige jeugd. 
 
Neem de tijd om te lezen, 
Dat is de grondslag van de wijsheid. 
 
Neem de tijd om aardig te zijn, 
Dat is de weg naar geluk. 
 
Neem de tijd om te dromen, 
Dat is de manier om hoog te mikken. 
 
Neem de tijd om te beminnen en bemind te worden, 
Dat is het voorrecht van de goden. 
 
Neem de tijd eens om, om u heen te kijken, 
De dag is te kort om zelflustig te zijn. 
 
Neem de tijd om te lachen, 
Dat is de muziek van je ziel. 
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INTRODUCTION 
 
1. Physiology of iron transport 
Iron is an essential element for all living organisms (1). Most of the body iron is 
found intracellularly; in ferritin, haemosiderin or haem present in haemoglobin, 
myoglobin and cytochromes. The iron which is found in extracellular body fluid 
is bound to high affinity iron-binding glycoproteins: transferrin in serum and 
lymph, and another related protein called lactoferrin in external secretions and 
milk (2). 
The distribution of iron in tissue is shown in Figure 1 (3).  
 
 
Figure 1. 
Distribution of iron in adults (N Eng J Med 1999;341(26):1986-1995). 
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More than two thirds of the body’s iron is incorporated into haemoglobin in 
developing erythroid precursors and mature red cells. Uptake of erythroid iron is 
highly dependent on receptor-mediated endocytosis of diferric transferrin bound 
to transferrin receptors (3). Each erythrocyte contains a billion atoms of iron; at 
normal rates of turnover, this concentration corresponds to the incorporation of  
2x1020 atoms of iron a day (4). Most of the remaining iron is found in 
hepatocytes and reticuloendothelial macrophages, which serve as storage depots. 
The liver has first-pass access to dietary nutrients and can readily take up an 
amount of circulating iron that exceeds the binding capacity of plasma 
transferrin. Reticuloendothelial macrophages ingest senescent red cells, 
catabolise haemoglobin to scavenge iron, and load the iron onto transferrin for 
reuse (3). 
Although the amount of iron extracted from the diet is small, the regulation of 
the intestinal absorption of iron is critical because humans have no physiologic 
way of excreting iron. Duodenal crypt cells sense the iron requirements of the 
body and are programmed as they mature into mature enterocytes. Enterocytes 
lining the absorptive villi close to the gastroduodenal junction are responsible 
for iron absorption. Iron must pass from the gut lumen through the apical and 
basolateral membrane of the enterocyte to reach the plasma (Figure 2). 
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Figure 2. 
Iron transport across the intestinal epithelium (N Eng J Med 1999;341(26): 
1986-1995). 
 
 
The low pH of gastric effluent facilitates enzymatic reduction of ferric (Fe3+) to 
its ferrous form (Fe2+) by brush border ferric reductase (5). Divalent metal 
transporter 1 (DMT1 or Nramp2 or DCT1) is a protein that transfers iron across 
the apical membrane and into the cell through a proton-coupled process (6,7). 
DMT1 is not specific to iron, it can transport a wide variety of divalent metal 
ions: manganese, cobalt, copper, zinc, cadmium and lead (7). Haeme iron is 
taken up by a separate process that is not well characterised.  
Inside the absorptive enterocyte, iron has two possible fates: it may be stored as 
ferritin, or it may be transferred across the basolateral membrane to reach the 
plasma. Iron that remains in the form of ferritin in the enterocyte will be 
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sloughed with the senescent cell and will leave the body through the 
gastrointestinal tract. This process represents an important mechanism of iron 
loss (3). Normally, the total amount of iron in the body is well controlled. There 
is no mechanism for iron excretion, and normally iron exits the body in tiny 
obligatory amounts (approximately 1 mg per day) during the loss of 
desquamated epithelial cells. In women, menstrual loss accounts for an 
additional 15-20 mg monthly (3). 
The basolateral enterocyte receptor for iron has not been identified, but a 
recently described protein, Ireg1, is a likely candidate (8). Genetic studies in 
mice have shown that the basolateral transporter requires an accessory protein, a 
multicopper protein called hephaestin (9). Another candidate could be 
ferroportin1, which has been identified as a conserved vertebrate iron exporter 
(10). 
The absorption of intestinal iron is regulated in several ways. It can be 
modulated by the amount of iron recently consumed in the diet, by the 
requirements for erythropoiesis or it can be regulated by the total body iron. 
Acute hypoxia increases iron absorption. It is not known whether the hypoxic 
signal is transduced through one of the regulatory pathways discussed above or 
through an independent mechanism (3,11,12).  
Transport of iron from one organ to another, is accomplished by a plasma 
protein called transferrin (13). Transferrin is the major iron-carrying protein in 
plasma and is  believed to regulate iron-fluxes between sites of absorption, 
storage and utilisation (2). Transferrin has a high binding affinity for iron (14). 
Transferrin is normally partially saturated, to the extent of 30-40 % (15). As a 
result there is virtually no freely available iron in normal body fluids (16). 
Transferrin receptors expressed by iron-requiring cells mediate the uptake of 
iron from transferrin by these cells (17,18). Transferrin receptors bind diferric 
transferrin and the receptor-transferrin complex is internalised into an 
endosome, where the iron is transferred to the cytosol. 
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The iron depleted transferrin, apotransferrin, recycles to the cell surface, where 
it dissociates from the transferrin receptor. Expression of cellular transferrin 
receptors is determined by the iron requirements of the cell (19,20).  
Iron is transported by transferrin to iron-requiring cells for subsequent 
incorporation into haem and many other iron-requiring cytoplasmic enzymes 
and proteins (2). Surplus iron is stored as ferritin and its derivative 
haemosiderin, in both parenchymal cells and mononuclear phagocytic system 
(21). Ferritin is the major iron storage protein and although it is found in almost 
all cells of the body, it is present in greatest concentration in the liver, spleen 
and bone marrow (22). The total body iron content is 3-4 g and of which nearly 
two thirds is present in haemoglobin in erythrocytes where it is required for 
oxygen transport (23).  
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2. Hereditary hemochromatosis  
A. Definition and clinical pattern 
Hereditary hemochromatosis (HH) is an autosomal recessive inherited 
disorder of iron metabolism that affects 1 in 200 to 1 in 400 persons of 
Northern European descent and is characterized by increased gastrointestinal 
iron deposition (24-26). It was first described in 1865 as a clinical triad of 
glycosuria, cirrhosis, and hyperpigmentation of the skin (27). Von 
Recklinghausen later established that these clinical features were due to iron 
deposition and coined the term hemochromatosis (28). The majority of 
patients with HH are descended from a common Celtic ancestor who lived 60 
to 70 generations ago (29). The Celts initially colonised Central, South-
Western, and South-Central Europe around 1000 BC. Settlements than 
dispersed to Belgium, the United Kingdom, Ireland, Spain, Scandinavia and 
Eastern Europe (Figure 3) (30).  
 
 
Figure 3 
The Celtic settlement and migration pattern during the Iron Age (Hepatology 
1997;25:1439-1446). 
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Patients with HH chronically absorb a small excess of iron, and middle-aged 
homozygotes frequently have 10 times normal body iron stores. As iron 
stores exceed the body’s capacity for effective chelation, free iron 
accumulates (31). Unbound iron is highly toxic, owing to its participation in 
the generation of free radicals and reactive oxygen intermediates. These 
molecules provoke peroxidation of membrane lipids leading to cellular 
injury, ultimately resulting in severe damage to the liver, heart, joints and 
endocrine organs. Liver damage may be exacerbated by alcohol consumption 
or viral hepatitis. The onset of the disease is insidious, and the initial 
manifestations are often non-specific symptoms, including fatigue and 
arthropathy. Before the detection of the genetic mutation, the diagnosis of 
hereditary hemochromatosis has been based on the documentation of 
increased iron stores, namely increased hepatic iron indices (of more than 1.9 
µmol/g dry liver tissue per year of life) associated with elevated serum 
ferritin levels. In the majority of the patients iron saturation is elevated (a cut-
off level of 52 % in the female and 62 % in the male population has been 
proposed) (32). 
If untreated, hemochromatosis invariably progresses and is ultimately fatal. 
However, if diagnosed before end stage organ damage, phlebotomy is an 
inexpensive, effective and life -saving treatment. Red blood cells are removed 
at regular intervals to deplete iron stores, and bone marrow erythropoiesis 
compensates effectively (31).  
 
B. Genetics of hemochromatosis  
The HH mutation has been known to be linked to the HLA region on the 
short arm of chromosome 6 since the mid 1970s (31,33). Twenty years later, 
in 1996, a positional cloning approach was used to detect a candidate gene 
for HH, now known as HFE. HFE codes for a novel MHC class I-like 
molecule that requires interaction with b2-microglobulin for normal 
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presentation on the cell surface (34). Structural homology with other MHC 
class I proteins and X-ray crystallographic studies indicate that the HFE 
protein has a large extracellular domain, a single transmembrane region, and 
a short cytoplasmatic tail (Figure 4) (33).  
 
 
Figure 4. 
Model of the HFE protein (Gastroenterology 2001;120:718-725). 
 
 
The large extracellular domain consists of 3 a domains, and a3 binds to b2-
microglobulin. HFE protein lacks a functional peptide-binding groove 
needed for antigen presentation (35).  
Two missense mutations have recently been identified in HFE; one results in 
a change of cysteine at position 282 to tyrosine (Cys282Tyr); the second 
results in a change of histidine at position 63 to aspartate (His63Asp) (34). 
 
In the original American study by Feder et al (34), 83 % of typical 
phenotypic HH patients were homozygous for the Cys282Tyr mutation, an 
additional 8 patients (5 %) were compound heterozygote, with one allele 
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containing the Cys282Tyr mutation and the other allele containing the 
His63Asp mutation. Afterwards, homozygosity for the Cys282Tyr missense 
mutation was confirmed in 64 % - 100 % of patients with typical phenotypic 
HH from the United States, France, Italy, Canada and Australia (25).  
Other mutations (eg. Ser65Cys) have recently been identified (36), but their 
frequency seems low, and thus their clinical impact may be limited.  
Recently, a pedigree from Italy was described with typical phenotypic HH 
but no mutations in the HFE gene, identifying a new inherited abnormality of 
iron overload (37). Mutations in the gene for transferrin receptor 2 can also 
result in iron overload (38). 
 
C. Pathophysiology of HFE 
Numerous studies have been performed to elucidate the pathophysiologic 
mechanisms of normal and dysregulated iron absorption. The creation of 
HFE-knockout mice and Cys282Tyr homozygous mice with a similar 
phenotype to that found in humans with HH, confirms that HFE is the gene 
responsible for HH (39-41). HFE protein is found in the crypt cells of the 
duodenum associated with b2-microglobulin and transferrin receptor (42,43). 
It has been hypothesised that HFE protein may facilitate transferrin receptor-
dependent iron uptake into crypt cells and that mutant HFE protein may lose 
this ability, leading to a ‘relative’ iron deficiency in duodenal crypt cells 
(Figure 5) (42-44). In turn, this may result in an increased expression of 
DMT-1 (3).  
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Figure 5. 
Critical steps in mammalian iron transport (Blood 1998;92(6):1845-1851) 
(31). 
 
 
Up-regulation of DMT-1 (Nramp2) expression has been confirmed in the 
HFE-knockout mice (45) and in humans with HH (46), providing supportive 
evidence for this pathophysiological mechanism. A similar mechanism may 
cause a status of  a ‘relative’ iron deficiency in monocytes-macrophages of 
patients with HH (47). 
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D. Genotypic/phenotypic correlations in HH 
The phenotypic expression of HH (homozygous for the Cys282Tyr missense 
mutation) may vary from a mere laboratory abnormality, namely an 
increased serum iron saturation to a fully penetrant clinical syndrome 
characterised by bronze pigmentation, cirrhosis, arthritis, endocrinopathy and 
cardiomyopathy (48).  
In a recent study (49), Crawford et al have demonstrated that 17.3 % of the 
subjects homozygous for the Cys282Tyr mutation do not fulfil the current 
diagnostic criteria of hemochromatosis. In another trial Olynyk et al have 
shown that only 50 % of the population homozygous for the Cys282Tyr 
mutation expressed clinical features of hemochromatosis, whereas one 
quarter has serum ferritin levels within the normal range during a four-year 
period (50). 
It is generally accepted that women and younger people have less severe 
phenotypic presentation of the disease. Iron overload develops at a slower 
rate in women with hereditary hemochromatosis than in men with the 
disorder, because in women iron stores are depleted by menstruation and 
pregnancy (50). Since hemochromatosis is a disease that progresses with 
time, younger people  have milder disease than older people (50). 
Recent reports have suggested that the phenotypic heterogeneity of 
hemochromatosis disease could be related to additional non-genetic causes, 
additional mutations or additional genes (51), and that one or more of these 
genes may be MHC-linked (52). 
Prior to the identification of the hemochromatosis gene, clinical variation in 
hemochromatosis has been primarily ascribed to genetic factors; haplotype/ 
phenotype analysis in several populations indicated that subjects with the 
predominant ancestral haplotype presented with a more severe clinical 
phenotype. 
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A recent study by Pratiwi et al (52) has demonstrated that in male Cys282Tyr 
homozygous patients also homozygous for this predominant ancestral  
haplotype (D6S265 to D6S2236 covering a regio of approximately 5 Mb) 
significantly higher hepatic iron indices are found than in patients 
heterozygous or nullizygous for this gene. Analogous data are observed by 
others (53,54). 
Alcohol intake is known to increase hepatic iron stores (55) and could be a 
non-genetic variable that influences the iron overload in C282Y homozygous 
individuals.  
 
E. The immunological system in hemochromatosis 
Various perturbations in the immune status of HH patients have been 
reported. Porto et al (56,57) found  high CD4+/CD8+ ratios in peripheral 
blood T lymphocytes in these patients. High ratios were positively correlated 
with the number of phlebotomies required to deplete iron stores and were not 
corrected after achieving normal iron status. The high ratios were due to a 
reduction in CD8+ cells (58). Within the decreased CD8+ compartment, an 
increased percentage of CD8+CD28- T cells, with a corresponding reduction 
in the percentage of CD8+CD28+T cells was also present in HH patients 
carrying the HLA-A3 allele. CD28 is a T-cell membrane protein which 
interacts with the co-stimulatory molecules B7.1 (CD80) and B7.2 (CD86) 
expressed by antigen presenting cells. CD28 expression was normal on 
CD4+ cells. CD8+CD28+ T cells from HH patients were capable of 
responding to exogenous mitogens. However, phytohaemagglutinin 
stimulation of peripheral blood mononuclear cells caused a decrease in 
CD8+CD28- T cells in healthy individuals but not in patients with hereditary 
haemochromatosis. CD8+ cytotoxic T lymphocytes also exhibited 
diminished cytotoxic activity (59). 
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Clearly, whether these immunological changes are directly tied to the 
absence of cell-surface molecules or are the secondary result of HH 
associated pathophysiological changes remains unclear. In a recent animal 
model, no difference in CD4 and CD8 subset T lymphocytes could be found 
between mice carrying the HFE missense mutation and those not carrying 
this missense mutation. This suggests that the described  differences are 
rather post therapeutic alterations or secondary manifestations of severe iron 
overload (41). 
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3. Non transferrin bound iron (NTBI) in disorders of iron metabolism 
A. The origin of NTBI 
NTBI comprises all forms of iron in the plasma that are bound to ligands 
other than transferrin (60). Upon binding to transferrin, iron becomes 
effectively shielded from reactions leading to redox cycling and formation of 
reactive oxygen species. The main sources of plasma iron are absorption via 
the gastrointestinal tract and recycling of aged erythrocytes by macrophages. 
Since plasma iron is normally maintained at levels far below transferrin-
binding capacity, its delivery to the plasma is believed to be tightly regulated 
(60). Thus when NTBI appears in the plasma, its is assumed to result from an 
imbalance in iron metabolism. It is observed in situations where transferrin  
becomes fully saturated, resulting in diminished plasma iron-binding 
capacity. Although paradoxical, NTBI has also been observed in situations 
where transferrin was not fully saturated, such as in patients with (early) HH 
(61-64) and dialysis patients (64).  In these situations iron must be entering 
the circulation in a form that is inaccessible to transferrin.  
There is sparse information about the biochemical nature of NTBI, but one 
may speculate that it is composed of  a heterogeneous mixture of complexes 
whose combination might vary with the degree and type of iron-overload.  
Analysis of NTBI in sera of patients with HH by HPLC (high-performance 
liquid chromatography) and high-resolution nuclear magnetic resonance 
indicated the presence of citrate-iron and ternary citrate-acetate-iron 
complexes (65). 
Albumin is another candidate ligand, and has been shown to form complexes 
with Fe3+ and with Fe2+-citrate in vitro. Although the affinity of albumin for 
trivalent metals is rather low, this might be compensated by its high 
concentration in serum (66).  
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The likelihood that serum ferritin contributes to NTBI is low (63). The 
ferritin found in  plasma tends to be iron-poor and the direct mobilization of 
iron from ferritin by various chelating and mobilizing agents is slow and 
inefficient unless reducing agents are used (67,68). 
 
B. Occurrence of NTBI 
It is generally accepted that NTBI is a pathological manifestation and is 
never found in healthy individuals. In principle, any condition or treatment 
that produces a short- or long-term iron load can give rise to NTBI. So NTBI 
is observed in 90 % of patients with haemolytic anaemia’s (69-72), in 69-90 
% of the patients with hereditary hemochromatosis (61-64,73), in 22 % of 
patients on haemodialysis (64), in patients on chemotherapy (79-97 %) (74-
76), during cardiopulmonary bypass (13 %) (77-79), in (premature) neonates 
(21-50 %) (80,81) and in patients with African iron overload disease (82). It 
is even observed in individuals heterozygous for the Cys282Tyr missense 
mutation (83). 
 
C. Detection of NTBI 
There are presently 3 main approaches to determine NTBI in biologic fluids. 
One approach uses the antibiotic bleomycin, which combines with NTBI, but 
apparently not with iron bound to transferrin or other proteins, to form highly 
reactive complexes that are quantified by the amount of DNA cleavage 
products that they generate (84). A second approach is based on mobilisation 
of NTBI with an anionic ligand (EDTA, citrate or nitrilotriacetate) followed 
by ultrafiltration and quantitation of the filterable iron by a colorimetric 
method, a method based on inductive plasma spectroscopy or by HPLC (64). 
The sensitivity and reproducibility of the colorimetric method are acceptable 
compared with the other two methods and would be more convenient as a 
routine screening assay for NTBI.  
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However, the limitations of this method are such that it can not be used in 
situations were desferrioxamine as an iron chelator therapy, is used (63). A 
third approach operates in a 96-well enzyme-linked immunosorbent assay 
format. A weak ligand, oxalic acid, mobilizes the NTBI and mediates its 
transfer to the iron chelator deferoxamine immobilised in the plate. The 
amount of deferoxamine-bound iron, originating from NTBI, is quantitatively 
revealed in a fluorescence plate reader by the fluorescent metallosensor 
calcein. This last method has the advantage of being technically simple and 
having a low labour intensity for an identical sensitivity and specificity (64). 
 
D. Is NTBI clinically important ? 
The transferrin molecule is specifically designed to transport iron in a readily 
available, soluble form and at the same time prevent its participation in redox 
reactions that could give rise to reactive oxygen species (85,86). Conversely, 
NTBI in the circulation could in principle be available for such reactions and 
lead to oxidative damage. There is much evidence correlating elevated tissue 
and plasma iron levels with depletion of antioxidants and various 
pathological conditions (87,88), such as chronic hepatitis C (89). Since the 
effects of iron overload are multifactorial, NTBI is likely to be only one of 
several contributing factors to the observed overall oxidative stress. There 
have been claims that elevated body iron stores may increase the risk of 
cardiovascular disease (90) and may catalyse the oxidation of low density 
lipoproteins, which is thought to be one of the triggers of atherosclerosis 
(91,92). In addition, the uptake of NTBI is not feedback-regulated (93), 
unlike the receptor-mediated uptake of transferrin bound iron (94). 
Conceivably, excess iron in the form of NTBI could be internalised by cells, 
mobilised within lysosomes and ultimately give rise to cellular iron overload 
(60). 
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The presence of NTBI inhibits lymphocyte proliferation; this effect is more 
striking on Th1 CD4+ T cells and CD8+ CTL. These data support the 
hypothesis that NTBI has an immunoregulatory role in cell-mediated 
immunity (95,96). 
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4. Hepatitis C virus infection (HCV) 
HCV is a RNA virus that belongs to the family of the flaviviruses (97). The 
natural targets of HCV are hepatocytes and possibly B lymphocytes (98,99).  
HCV encodes a single polyprotein of 3011 amino acids, which is  processed 
into 10 mature structural and regulatory proteins (Figure 6) (100). 
 
 
Figure 6. 
The HCV genome (N Eng J Med 2001;345(1):41-52). 
 
 
Structural components include the core protein and two envelope proteins: 
E1 and E2. Two regions of the  E2 protein, designated hypervariable regions 
1 and 2, have an extremely high rate of mutation, believed to be the result of 
selective pressure by virus-specific antibodies (100). E2 also contains the 
binding site for CD81, which is thought to act as a cellular receptor or 
coreceptor for the virus on hepatocytes and B lymphocytes (101). HCV also 
encodes a virus-specific helicase, protease and polymerase (100).  
Six distinct but related HCV genotypes and multiple subtypes have been 
identified. In the United States and Western Europe genotypes 1a and 1b are 
most common, followed by genotypes 2 and 3 (100). 
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The prevalence of HCV infection varies throughout the world, with the 
highest number of infections reported in Egypt (102). In the Unites States 1.8 
% of the population is positive for HCV antibodies (103). In Belgium the 
number of persons positive for HCV antibodies is estimated to be 0.9 % of 
the population (104).  
The factors most strongly associated with infection are injection-drug use and 
receipt of blood transfusion before 1990 (103), but in some cases no risk 
factor can be identified (105,106). Maternal-fetal transmission occurs but is 
infrequent (107). Sexual transmission of the virus is also uncommon (108).  
After infection with the virus, only a minority of the patients spontaneously 
clears the virus. Sixty to 80 % of the patients with an acute HCV infection 
evolves towards chronicity. After 20 years, cirrhosis develops in 20 % of 
them. In those having cirrhosis, the annual risk of developing a 
hepatocellular carcinoma is 5-7 % (109,110). 
The immune response to viral antigens is thought to be responsible as well 
for viral clearance as for disease pathogenesis during chronic HCV infection. 
In chronically infected patients, the T cell response to the HCV is polyclonal 
and multispecific, although it is not as strong as the response in acutely 
infected patients who develop a more vigorous T-cell response. Thus the 
dominant cause of viral persistence during HCV infection may be the weak 
antiviral immune response to the viral antigens, and the ensuing inability to 
eradicate infected cells (111).  
The diagnosis of hepatitis C virus infection is made by detection of HCV 
antibodies. The presence of circulating virus is demonstrated by HCV PCR. 
Qualitative and quantitative HCV RNA assays as well as HCV genotyping 
assays are available. Alanine aminotransferase (ALT) is an important non-
specific laboratory test to identify hepatic disease. 
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However, in persons with HCV infection ALT levels may be normal or 
fluctuate, and therefore a single normal value does not rule out active 
infection, progressive liver disease, or even cirrhosis (112).  
Histological evaluation of a liver-biopsy specimen remains the gold standard 
for determining the activity of HCV-related liver disease, and histological 
staging remains the only reliable predictor of disease progression (113).  
Monotherapy for HCV infection with interferon alfa is associated with initial 
response rates of 40 percent, but the rates of sustained virological response 
are less than 20 percent (114,115). This is especially true for persons infected 
with HCV genotype 1a or 1b. Two large, prospective trials demonstrated that 
the combination of interferon alfa (3 MU thrice weekly subcutaneous) and 
ribavirin (1000-1200 mg per day, orally) during a period of 6 to 12 months, 
increased the percentage of sustained virological response in previously 
untreated patients from 16 to 40 percent (114,115). Both studies showed that 
in patients infected with  HCV genotype 2 or 3 and in those with low viral 
loads (less than 2 million copies of virus/ml) before treatment, the response 
was maximal after 24 weeks of treatment. Patients infected with genotype 1 
and those with a high viral load (higher than 2 million copies of virus/ml) 
before treatment required a course of 48 weeks for an optimal outcome. 
Therefore the EASL (European Association for the Study of the Liver) 
recommended the above-described regimes for treatment of untreated 
patients (116).  
The chemical coupling of polyethylene glycol to interferon alfa 
(peginterferon alfa) extends the biological half-life and duration of activity of 
interferon alfa. In contrast to interferon alfa, which is given 3 times a week, 
peginterferon alfa is given only once a week. Treatment with peginterferon 
alfa results in a higher rate of sustained response than does conventional 
monotherapy with interferon alfa (39 % versus 19 %) (117). 
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Combining peginterferon alfa with ribavirin also increases the frequency of 
sustained response, when compared with peginterferon in monotherapy 
(118,119). 
The side effects of the treatment are those related to (peg)interferon alfa and 
ribavirin. (Peg)interferon alfa mainly induces influenza-like symptoms, 
headache, fatigue, fever, myalgia, anorexia, irritability, thrombocytopenia, 
leukocytopenia, thyroid dysfunction …  
Ribavirin is a water soluble synthetic guanosine analogue that exerts antiviral 
activity against DNA and RNA viruses after intracellular phosphorylation 
(120). Ribavirin also has immunomodulating capacities: it diminishes Th2 
cytokine production while preserving Th1 cytokine production (121). The 
major side effect of ribavirin treatment is the occurrence of a reversible 
haemolytic anaemia in a substantial portion of treated patients (122). The 
underlying mechanism is unknown. Studies on steady-state pharmacokinetics 
of ribavirin have shown that the erythrocyte concentration of ribavirin greatly 
ex ceeds plasma concentrations (123) and that ribavirin is a transported 
permeant for a nucleoside transporter in human erythrocytes (124). Ribavirin 
is converted intracellularly to its corresponding triphosphate, producing a 
relative adenosine triphosphate deficiency in erythrocytes (125-127). The 
lowering of the intracellular adenosine triphosphate level may indirectly 
affect and lower the antioxidant defence mechanisms. The pro-oxidant 
phenomenon may induce a premature erythrocyte senescence and phagocytic 
removal (120). Haemolytic anaemia is the main side effect of ribavirin. 
Ribavirin also causes nausea, nasal congestion and seldomly gout (100). 
 30
 5. Iron and chronic hepatitis C virus infection 
It is generally accepted that iron increases the formation of hydroxyl radicals 
and other highly reactive oxidizing molecules in biological systems (128). 
Secondary reactions and indirect effects lead to lipid peroxidation, oxidative 
damage to proteins and nucleic acids, and to a net increase in collagen and 
ground substance formation. In iron-overloaded livers, such changes produce 
defects in organelle function (lysosomes, mitochondria, endoplasmic 
reticulum) and chronic deposition of scar tissue and eventual hepatocellular 
carcinoma (129,130). 
Although in viral hepatitis the role of the host’s immune system in causing 
hepatic damage is much more important than in the case of pure iron 
overload, changes attributed to iron also occur in chronic viral hepatitis. 
Evidence of increased lipid peroxidation has been identified consistently in 
plasma (131) and liver biopsies (132) of patients with chronic hepatitis C, 
compared with healthy controls or patients with chronic hepatitis B. If the 
stored iron seen in the liver of patients with chronic hepatitis C is the cause 
of these changes or only a consequence of hepatic inflammation caused by 
the virus remains speculative. 
In chronic hepatitis C virus infection, serum iron concentration is elevated in 
27-36 % of the patients, transferrin saturation in 18-24 % and serum ferritin 
concentration in 22-35 % (133,134). A strong correlation is seen between 
serum ferritin levels and AST levels, suggesting that release of tissue ferritin 
from damaged hepatocytes is an important mechanism for the elevations in 
serum iron studies (134). Increased serum iron studies are more common in 
chronic hepatitis C virus infection than in patients with chronic hepatitis B 
virus infection (135). 
 
 
 
 31
Hepatic iron concentration (HIC) is also elevated in patients with chronic 
hepatitis C, but less frequently than serum transferrin saturation or ferritin. 
The frequency of elevated HIC ranges from 10 to 36 % in patients with 
chronic hepatitis C (134,136,137). The elevation in HIC and HII (hepatic iron 
index, which is the HIC divided by the age in years of the patient) is usually 
mild, with a mean HII of 0.4-0.6 µmol/g/age (137,138). HIC does not appear 
to correlate with HCV RNA levels (139) and the effect of different genotypes 
is controversial (140,141). The presence of stainable hepatic iron has been 
shown to correlate with inflammation and fibrosis. This correlation could be 
a threshold effect: once inflammation or fibrosis is present, increases in iron 
appear to have no further linear correlation with increased inflammation or 
fibrosis (142). 
In end-stage liver disease, even in the absence of the HFE missense mutation, 
iron accumulation can be significant and reaching HII values of greater than 
1.9 µmol/g dry liver tissue per year of life; values which were in the past 
(before the HFE mutation era) pathognomonic for hereditary 
hemochromatosis (143-146).  
Unlike hepatic iron accumulation in hereditary hemochromatosis, the mild 
hepatic iron overload often seen in patients with compensated liver disease 
due to hepatitis C does not appear to progressively increase in time, despite 
the worsening of the hepatic inflammation in a certain amount of patients. 
These findings suggest that hepatic iron accumulation is multifactorial and 
not solely related to the degree of inflammation or fibrosis (147).  
The hepatic iron accumulation in patients with chronic hepatitis C is more 
often seen in the Kuppfer cells than in patients with hereditary 
hemochromatosis where iron accumulates in the parenchyma (148). 
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After a treatment with interferon alfa, a decrease in HIC is observed in both 
virologic responders and nonresponders. Histologically, the decrease in 
stainable iron is predominantly seen in mesenchymal cells as opposed to 
hepatocytes. These findings suggest that the elevations observed in chronic 
hepatitis C are primarily due to phagocytosis of necrotic hepatocytes and 
accumulation of iron in phagocytic cells. The decrease of HIC seen in 
nonresponders may reflect a reduction in inflammation despite failure to 
clear viremia (148). 
After treatment with ribavirin and highly plausible due to the ribavirin 
induced haemolysis and related iron release, stainable hepatic iron 
significantly increased. This was associated with an increase of HIC. After 
treatment with ribavirin, iron is deposited mainly in the hepatocytes 
(149,150). 
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6. Haptoglobin polymorphism 
Haptoglobin (Hp) is an a2-sialoglycoprotein with haemoglobin (Hb)-binding 
capacity (151,152). The best-known biological function of Hp is capture of 
Hb to prevent both iron loss and kidney damage during haemolysis (153). Hp 
is also an acute-phase protein and is characterized by a molecular 
heterogeneity with three major phenotypes: Hp 1-1, Hp 2-1 and Hp 2-2 (151-
154). Using starch gel electrophoresis, the three major phenotypes can be 
identified (155). These phenotypes are genetically determined by two alleles:  
Hp1 and Hp2 (151,152). The homozygote Hp1/Hp1 shows a single fast-
migrating Hp1-1 protein band on starch gel electrophoresis. The homozygote 
Hp2/Hp2 has a series of slower migrating bands. The heterozygote Hp1/Hp2 
displays another series of slow bands and a weak Hp 1-1 band. Hp consists of 
two different polypeptide chains, the a-chain and the b-chain (151,152). The 
b-chain (40 kDa) is heavier than the a-chain and is identical in all Hp types. 
The a-chain shows three major forms: a1S, a1F (s=slower, f=faster) and the 
slow migrating a2-chain. The Hp 1-1 phenotype expresses only a1-chains, 
a²-chains are present in Hp 2-1 and Hp 2-2 (151,152). The loci involved for 
the Hp synthesis are located on chromosome 16q22. The Hp 1-1 is a small 
molecule (86kDa) with formula (a1b)2. Heterozygote Hp 2-1, (a1b)2 + (a2b)n 
(n=0,1,2,...), is characterized by polymerisation. Hp 2-2 comprises higher 
molecular mass forms (>200 kDa) with formula (a2b)n (n=3,4,5,...) 
(154,156). 
The synthesis of Hp is considerably lower in fetal than in adult liver (151). 
The hepatic synthesis of Hp is induced by cytokines such as interleukin-6, 
interleukin-1 and tumor necrosis factor (151,157).  
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The haptoglobin concentration is Hp phenotype dependent. The reference 
range of the haptoglobin concentration is lower in individuals carrying the 
Hp 2-2 phenotype than individuals carrying the Hp 1-1 and Hp 2-1 
phenotype (158).  
The haptoglobin phenotype distribution differs according to geographical 
localisation of the population studied (159). In Belgium the phenotype 
distribution in a healthy population is: Hp 1-1: 16 %, Hp 2-1: 48 % and Hp  
2-2: 36 % (160). 
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The haptoglobin protein has different functional properties 
 
a. Binding haemoglobin 
Hp forms a soluble complex with Hb. The binding of Hp with Hb is 
characterised by a high affinity (161). After destruction of erythrocytes, free 
Hb in the circulation passes through the glomerular filter and renal damage 
may occur. Hp reduces the loss of Hb and iron, because the Hb-Hp complex 
is not filtered through the glomeruli but is transported to the liver (153). Hb 
binding depends not only on serum concentration of Hp but also on Hp 
phenotype (162). The haemoglobin binding capacity is lowest in persons 
with the Hp 2-2 phenotype and highest in Hp 1-1 individuals (162).  
 
b. Protection against free radicals  
Free Hb promotes the accumulation of hydroxyl radicals (163). Haeme iron 
catalyses the oxidation of low-density lipoproteins, which can damage 
vascular endothelial cells (164). These dangers are reduced by the phenotype 
dependent Hb-binding capacity of Hp (162,165). Breakdown of erythrocytes 
in the interstitial fluid results in Hb-mediated .OH formation. The distribution 
of highly polymeric Hp 2-2 proteins in extravascular fluids is restricted by 
their molecular mass (154). Consequently, the antioxidative capacity of body 
fluids is less effective in Hp 2-2 individuals (154). 
 
c. Inhibition of prostaglandin synthesis 
Hp is an endogenous inhibitor of prostaglandin synthesis (166,167). The 
inhibitory effects of Hp 2-2 and Hp 2-1 are less pronounced than that of Hp 
1-1 (154).  
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d. Bacteriostatic effect 
As a consequence of the capture of free Hb by Hp, haeme iron is unavailable 
for bacterial growth (168). An iron-restrictive environment established by Hp 
is part of the non-specific defence against bacterial infection. 
 
e. Angiogenesis 
Hp has been identified as one of the serum angiogenic factors required for 
proliferation and differentiation of endothelial cells in the formation of new 
blood vessels (169,170). Hp 2-2 is more angiogenic than the other 
phenotypes (169).  
 
f. Immunological properties 
Human serum from Hp 2-2 and Hp 2-1 individuals agglutinates the 
Streptococcus pyogenes group A, carrying the T4 antigen. The Hp 2-2 serum 
has higher agglutination titres than the Hp 2-1 serum. In contrast, Hp 1-1 has 
no agglutination effect. Hp is not a true antibody because it does not possess 
the highly variable antigen-binding sites characteristic for the Fab moiety of 
immunoglobulins. The agglutination is probably mediated via binding with 
lectin-like structures (171,172). 
Comparison of reference values for lymphocyte subsets in peripheral blood 
and bone marrow show significant differences between haptoglobin 
phenotypes. Hp 2-2 is associated with higher peripheral B-lymphocyte counts 
and CD4+ T-lymphocytes counts. In contrast, in bone marrow, CD4+ T-cell 
percentages are high but B-cell percentages low in Hp 2-2 type. Flow 
cytometric analysis demonstrates that Hp binds to human B-lymphocytes via 
the CD22 receptor. Although the affinity of the binding is the same for the 
three phenotypes, the number of free CD22 binding sites is estimated to be 
higher in Hp 2-2 blood. No significant binding is detected for T-cells and 
NK-cells (173). 
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g. Influence on iron status 
In males but not in females, the Hp 2-2 phenotype is associated with higher 
serum iron, transferrin saturation and ferritin concentrations than in the      
Hp 1-1 and Hp 2-1 phenotype, whereas soluble transferrin concentrations are 
lower. Serum ferritin correlated with monocyte L-ferritin content which is 
also highest in the male Hp 2-2 subgroup (174). CD163 has been identified 
as the monocyte-macrophage receptor binding the Hb-Hp complex. CD163 
binds only haemoglobin and haptoglobin in complex, which indicates the 
exposure of a receptor-binding neoepitope. Complexes of haemoglobin and 
multimeric Hp 2-2 haptoglobin exhibit higher functional affinity for CD163 
than do complexes of haemoglobin and dimeric Hp 1-1 haptoglobin (175).  
 
Considering the different properties of the haptoglobin phenotype, the 
polymorphism has demonstrated to have an effect on different clinical 
entities (159). The higher immune reactivity of the Hp 2-2 phenotype results 
in an overrepresentation of this phenotype in autoimmune diseases (176,177) 
and an underrepresentation in malignancies (178-181). Depending on the 
nature of the antigen, differences in antibody titre after vaccination are seen 
between the Hp phenotypes (182-184).  
Associations between Hp phenotypes and atherosclerotic disorders have been 
demonstrated. However, it remains unclear whether the role of Hp in 
development of atheromatous lesions can be attributed to inhibition of local 
oxidative stress or to modulation of immune and inflammatory reactions 
(185-187). 
HIV patients carrying the Hp 2-2 show a worse prognosis. This is attributed 
to a less effective protection against iron-driven oxidative stress (188).
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AIMS OF THE WORK 
 
Since the HFE mutation and the haptoglobin polymorphism influence the iron 
storage capacity (1,2) and are related with different immunological properties 
(3,4), we studied the effects of these gene polymorphisms on two diseases 
associated with iron accumulation.  
Hereditary hemochromatosis is the most frequent genetically influenced iron 
storage disease in Western Europe (5). Before the discovery of the HFE 
mutation in 1996, clinicians had to rely on the phenotypic presentation and the 
hereditary character of the disease to establish the diagnosis. After the 
recognition of the HFE mutation (6), it became clear that not all individuals with 
the Cys282Tyr missense mutation behaved identically and expressed the 
phenotype of hereditary hemochromatosis (7).  
Due to its effect on iron metabolism, the haptoglobin polymorphism could alter 
the clinical presentation, prognosis and perhaps treatment of patients with 
hereditary hemochromatosis. 
The first part of this work investigated: 
 
a) Whether Flemish patients which were classified as having hereditary 
hemochromatosis before the recognition of the HFE missense 
mutation, carried the Cys282Tyr  and/or the His63Asp missense 
mutation. 
b) Whether the haptoglobin polymorphism had influence on the 
phenotypic expression of Cys282Tyr homozygous hereditary 
hemochromatosis. 
c) Whether the percentage of CD163 monocyte-macrophage receptors 
differed between the different haptoglobin phenotypes in healthy males 
and whether the number of CD163 receptors differed in patients with 
hereditary hemochromatosis. 
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Chronic hepatitis C is a second disease associated with a largely unexplained 
iron overload and higher oxidative stress (8,9). Moreover, ribavirin, which has 
become a standard part of the treatment of chronic hepatitis C, causes higher 
serum and liver iron levels. Probably this phenomenon is due to the haemolytic 
anaemia induced by ribavirin treatment (10). 
Since both the HFE missense mutation and the haptoglobin polymorphism could 
alter, through their effect on iron metabolism and differences in immunological 
response, the progression to chronicity, iron status and response to treatment in 
patients with chronic hepatitis C infection, its is interesting to evaluate the 
influence of these two variables in these patients. 
 
The second part of this work investigated: 
 
a) Whether the frequency of the HFE missense mutation and the 
distribution of the haptoglobin phenotypes differed between chronic 
hepatitis C patients and a healthy control population.  
b) Whether these two factors (HFE missense mutation and haptoglobin 
polymorphism) were associated with each other and had influence 
upon the clinical presentation of chronic hepatitis C virus infection. 
c) Which pre-treatment factors influenced the degree of ribavirin-induced 
haemolysis. 
d) Whether NTBI was present in patients with chronic hepatitis C and 
whether treatment with ribavirin might induce the appearance of 
NTBI. 
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ABSTRACT 
 
Introduction 
The monocyte-macrophage receptor CD163 has been  shown to be the receptor 
of haemoglobin-haptoglobin (Hb-Hp) complexes. The binding of the Hb-Hp 
complexes is haptoglobin phenotype dependent, resulting in a higher 
macrophage iron content in Hp 2-2 individuals. We determined the percentage 
of CD163+CD33+ monocytes-macrophages in patients with different 
haptoglobin phenotypes and in patients with hereditary and secondary 
hemochromatosis. 
Materials and methods 
The percentage of CD163+ CD33+ peripheral blood monocytes was determined 
by flow cytometry. The percentage in 30 male volunteers with different 
haptoglobin phenotypes was determined and compared with the percentage in 16 
patients with hereditary hemochromatosis and 5 patients with secondary iron 
overload.   
Results  
In the healthy volunteers there was no difference in the percentage of 
CD163+CD33+ monocytes-macrophages between the different haptoglobin 
phenotypes. No difference was found in the percentage of CD163+CD33+ 
monocytes-macrophages between patients with hereditary hemochromatosis ( 67 
± 23) or secondary hemochromatosis ( 58 ± 27) versus controls ( 54 ± 22). 
Discussion 
There is no haptoglobin related difference in the percentage of CD163+CD33+ 
monocytes-macrophages. The data in the patients with hereditary and secondary 
hemochromatosis argue against a relationship between the relative number of 
CD163+CD33+ circulating cells and iron metabolism. 
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Introduction 
CD163 is a member of the scavenger receptor cysteine-rich group B family of 
proteins. Members of this family contain highly conserved scavenger receptor 
(SRCR) domains, and include the type I scavenger receptor, CD5, CD6 and 
WC1 (found on bovine g d T cell) (1). SRCR proteins are typically associated 
with immune functions and are expressed on a number of different cells of the 
immune system (2). CD163 expression is restricted to cells of monocyte lineage 
and increases as monocytes mature into macrophages (3). The mRNA and 
protein levels of CD163 are tightly controlled by inflammatory regulators. 
Whereas proinflammatory stimuli like lipopolysaccharide or IFN-g suppress its 
expression, anti-inflammatory molecules like glucocorticoids or IL-10 strongly 
induce CD163 on monocytes and macrophages (4,5).  
Recently CD163 was demonstrated to act as a receptor that scavenges 
haemoglobin by mediating endocytosis of haemoglobin-haptoglobin complexes. 
Haemoglobin released into plasma is captured by the acute phase protein 
haptoglobin, which is depleted from plasma during elevated haemolysis. 
Efficient removal of free haemoglobin is essential for health  because of the 
oxidative and toxic properties of iron-containing haem in haemoglobin. CD163 
binds only haptoglobin and haemoglobin in complex, which indicates the 
exposure of a receptor-binding neoepitope (6). 
In humans, three major haptoglobin (Hp) variants exist: Hp 1-1, Hp 2-2 and the 
heterozygous Hp 2-1 (7). Complexes of haemoglobin and the multimeric 
haptoglobin (Hp 2-2) exhibit higher functional affinity for CD163 than do 
complexes of haemoglobin and dimeric haptoglobin (Hp 1-1) (6). In healthy 
male Hp 2-2 subjects the serum ferritin and the L-ferritin concentration in 
monocytes-macrophages are higher than in Hp 1-1 subjects (8). This could be 
the consequence of the higher affinity of the Hp 2-2 – haemoglobin complex for 
the CD163 receptor. 
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Hereditary hemochromatosis is a very common autosomal recessive disease of 
iron metabolism. Recently the HFE mutation was found to be present in the 
majority of the patients with hereditary hemochromatosis. Despite intensive 
investigations, the cellular location of the defect is still controversial. In fact, the 
liver, duodenum and reticuloendothelial system have all been proposed as the 
primary site of the metabolic abnormality (9). 
It is known that iron storage in macrophages differs depending on the cause of 
iron accumulation (10). In secondary iron overload, as a result of 
dyserythropoiesis, haemolysis or transfusions, macrophages are heavily loaded 
with iron. In contrast, in hereditary hemochromatosis, little iron is seen in the 
Kupffer cells and other macrophages, while hepatocytes already suffer from iron 
overload. In both forms of iron overload, low-molecular weight complexes of 
iron are observed in the plasma. Iron overload of macrophages in secondary 
hemochromatosis can be explained partially by the fact that these cells must 
process large quantities of (immature) erythrocytes, while the primary cause of 
iron overload in hereditary hemochromatosis is an inappropriately increased 
absorption of iron. However, defects in erythrophagocytosis or differences in 
cellular iron processing and iron release may contribute to the low amounts of 
iron in the macrophages of patients with hereditary hemochromatosis (10). 
Considering the relative low iron content in monocytes-macrophages seen in 
patients with hereditary hemochromatosis, we examined if the percentage of 
CD163+CD33+ monocytes-macrophages differed in patients with hereditary 
hemochromatosis from normal control subjects and from patients with 
secondary hemochromatosis. 
We also studied the relationship between the haptoglobin polymorphism and the 
percentage of CD163+CD33+ monocytes-macropaghes in healthy male 
individuals. 
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Materials and methods 
Subjects 
Thirty healthy male volunteers were recruited from the hospital staff of the 
Ghent University Hospital. Blood was sampled for CD163 expression, amino 
alanine transferase activity, serum iron, serum transferrin, serum ferritin, C-
reactive protein, haptoglobin concentration and haptoglobin phenotype. 
Considering the influence of inflammation on CD163 expression, only 
volunteers with a normal C-reactive protein  (CRP < 1,2 mg/dl) were included. 
These volunteers were used as controls. 
Sixteen patients ( 13 male, 3 female) with Cys282Tyr homozygous hereditary 
hemochromatosis were recruited from the out-patient clinic of the department of 
Gastroenterology, Ghent University Hospital. Informed consent was obtained. 
Blood was taken during a therapeutic phlebotomy session. Six patients were on 
a schedule of weekly phlebotomy to achieve serum ferritin levels of less than 50 
µg/l, the other 10 received phlebotomy on an average schedule of 3 to 4 times a 
year to keep serum ferritin at a level of 50 µg/l.  
Five patients with secondary iron overload as a result of multiple blood 
transfusions for the symptomatic treatment of myelodysplastic syndrome (n=4) 
or aplastic anaemia (n=1) were recruited from the department of Haematology.  
 
Biochemical analysis 
Blood samples were obtained, allowed to clot and centrifuged. The supernatant 
serum was collected for analysis. Serum iron concentration, total iron binding 
capacity (TIBC), serum alanine aminotransferase (ALT) activity  and C-reactive 
protein were  determined using commercial reagents (Roche). 
Transferrin saturation was calculated by the formula: 
   100 x (serum iron/TIBC). 
Serum ferritin concentration and serum haptoglobin concentration were 
measured using fixed-time immunonephelometry (Dade Behring). 
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Determination of the haptoglobin phenotype 
The Hp phenotypes were determined using starch gel electrophoresis of 
haemoglobin-supplemented serum followed by peroxidase staining (11). 
 
HFE missense mutation 
The Cys282Tyr missense mutation was searched for according to the method 
described by Feder et al (12). In short, after extraction of genomic DNA from 
peripheral blood mononuclear cells DNA was amplified by PCR technique. 
After amplification these fragments were further investigated by restriction 
enzyme digestion followed by agarose gel electrophoresis. The missense muta-
tion Cys282Tyr resulted in an additional restriction site for the restriction 
enzyme RsaI. Homozygotes, heterozygotes or normals were easily recognized. 
Recently, a polymorphism in intron 4 of HFE was described causing an 
overestimation of the Cys282Tyr homozygote prevalence in hemochromatosis. 
We examined all samples using a new antisense primer that excluded the site of 
the new polymorphism (13,14). 
 
CD163 expression 
Peripheral blood mononuclear cells (PBMC) were isolated from 10 ml 
heparinized blood by Ficoll-Paque 1077 gradient (Pharmacia, Upssala, Sweden) 
centrifugation. The PBMC were transferred into separate wells of a 24 well 
culture plate (Gibco BRL, Grand Island, USA) and incubated for 24 hours in 
RPMI 1640 medium (Gibco BRL) containing 10 % autologous plasma. The 
cultured cells were harvested, resuspended in phosphate buffered saline (PBS) 
and incubated for 30 min in the dark in the refrigerator with the following 
fluorochrome labelled monoclonal antibodies against cell surface markers: anti-
CD33 APC (monocytes, macrophages, clone P67.6, Becton Dickinson, San 
Diego, USA) and anti-CD163 PE (clone GHI/61, Pharmingen, San Diego, 
USA). 
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Isotype and concentration matched control monoclonal antibodies with PE and 
APC were used as controls. Subsequently, the cells were washed with PBS, 
resuspended in PBS and analysed by flow cytometry using a FACSort (Becton 
Dickinson). Data were analysed using Cellquest software (Becton Dickinson). 
Monocytes were identified using a forward and side scatter gate  in combination 
with a gate for CD33 positive cells. CD163 expression was determined as the 
percentage of CD33 positive monocytes (Figure 1). 
 
Statistical analysis  
Statistics were performed using the Medcalc program version 5.00.002 (15). 
Normality of the distribution of the different variables was tested using the 
Kolmogorov-Smirnov test. Variables with a normal distribution are presented as  
mean ± standard deviation. Variables with a non-Gaussian distribution are  
presented as median and  interquartile range.  
Parametric and non-parametric tests were used according the distribution of the 
variable. P-values of < 0.05 were considered significant.  
 
Ethics  
The protocol was approved by the Ethical Committee of the Ghent University 
Hospital.  
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Results  
Healthy volunteers 
All male volunteers have normal C-reactive protein levels (cf. selection criteria) 
and normal ALT activity. Serum iron studies, haptoglobin concentrations and 
percentage of CD163+CD33+ monocytes-macrophages are shown in Table 1. 
The mean age of the group is 33 years ± 8. The haptoglobin phenotypes 
distribution was: Hp 1-1: 6, Hp 2-1: 16 and Hp 2-2: 8. The percentage of 
CD163+CD33+ monocytes-macrophages, serum iron studies and haptoglobin 
concentration according the haptoglobin phenotype are shown in Table 2. There 
is no difference in the percentage of CD163+CD33+  monocytes-macrophages 
between the different haptoglobin phenotypes. Haptoglobin concentration is 
clearly haptoglobin phenotype dependent (Table 2). 
No correlation is seen between the percentage of CD163+CD33+ monocytes-
macrophages and age, serum iron, serum iron saturation and serum ferritin 
concentration. 
 
Patients with hereditary hemochromatosis 
The mean age of the 16 patients with hereditary hemochromatosis is 55 years ± 
9. This is older than the group of healthy volunteers (p<0.01). Serum iron 
studies and percentage of CD163 cells are presented in Table 1. 
Serum iron and iron saturation are higher in patients than in controls (p<0.02 
and p<0.01). Serum ferritin concentration is not higher in patients than in the 
healthy controls, reflecting that the patients are adequately treated to achieve 
serum ferritin concentrations of lower than 50 µg/l. However the range in serum 
ferritin concentration is higher in the patient group than in the control group 
(Table 1). C-reactive protein concentration is normal in all 16 patients. 
The percentage of CD163+CD33+ monocytes-macrophages is not significantly 
different in patients with HH than in controls. 
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In the patient group, there is no correlation between the percentage of 
CD163+CD33+ monocytes-macrophages and serum iron studies. In particular, 
the percentage of CD163+CD33+ monocytes-macrophages is not different 
between patients with elevated serum ferritin concentrations and those with 
normal serum ferritin concentrations (73±17 versus 57±30, p=0.2). 
 
Patients with secondary hemochromatosis 
The mean age of the 5 patients with secondary hemochromatosis is 63 years ± 
16 (p<0.001 versus the control population, p=0.3 versus the patients with 
hereditary hemochromatosis). Serum iron studies and percentage of CD163+ 
cells are presented in table 1. 
C-reactive protein concentration is higher than normal (5.6 mg/dl) in one 
patient; the percentage of CD163+CD33+ positive monocytes-macrophages is 
30 % in this patient.  
The percentage of CD163+CD33+ positive monocytes-macrophages is not 
different in patients with secondary hemochromatosis as compared to controls 
and patients with hereditary hemochromatosis. In patients with secondary 
hemochromatosis no correlation is found between the percentage of 
CD163+CD33+ monocytes-macrophages and serum iron studies. 
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Discussion 
Recently the CD163 protein was shown to act as a receptor that scavenges 
haemoglobin-haptoglobin complexes and a higher affinity of the receptor for 
haemoglobin-Hp 2-2 complex than for the haemoglobin-Hp 1-1 complex was 
observed (6). In healthy males, it has been demonstrated that the subjects with 
the Hp 2-2 phenotype have higher serum ferritin and monocyte ferritin content 
than subjects carrying the Hp 1-1 and 2-1 phenotype. A good correlation has 
been demonstrated between serum ferritin concentration and monocyte L-ferritin 
content (8). In our control group of 30 male healthy volunteers there is neither a 
difference in the percentage of CD163+CD33+ monocytes-macrophages 
between the different haptoglobin phenotypes nor a correlation between the 
percentage of CD163+CD33+ monocytes-macrophages and serum iron indices. 
Thus the higher serum and monocyte ferritin content in Hp 2-2 subjects seems to 
be solely the consequence of the higher affinity of the haemoglobin-Hp 2-2 
complex for the CD163 receptor, and not of a higher percentage of 
CD163+CD33+ monocytes-macrophages in the Hp 2-2 subjects. 
In patients with hereditary hemochromatosis, the monocyte-macrophage has a 
relative iron-poor content in comparison with the abundant iron which is present 
in the body (10,16). This can be attributed to different mechanisms. It is known 
that patients with hereditary hemochromatosis have a significantly decreased 
ability to phagocytose red blood cells (17). It is also established that after 
erythrophagocytosis, monocytes of patients with hereditary hemochromatosis,  
release twice as much iron in a low molecular weight form as control cells (10). 
In macrophages of patients with hereditary hemochromatosis a significant 
increase in iron regulatory protein (IRP) activity is demonstrated (9). By 
preventing ferritin mRNA translation, high IRP activity in monocytes may 
represent a molecular mechanism contributing to the inadequate ferritin 
accumulation and insufficient macrophage iron storage in hereditary 
hemochromatosis. 
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IRP is a cytoplasmic sensor of the labile iron pool which is regarded as one of 
the main regulators of cellular iron homeostasis. The upregulation of IRP in 
hereditary hemochromatosis is monocyte-macrophage specific, since it is absent 
in other circulating blood cells. Moreover this abnormality seems characteristic 
of the genetic form of hemochromatosis, as a reduced IRP activity is found in 
patients with secondary hemochromatosis. However, after phlebotomy in 
patients with hereditary hemochromatosis, iron regulatory protein activity did 
not differ form that of control subjects (9).  
Since the CD163 receptor could contribute, via the uptake of haeme-iron of the 
haemoglobin-haptoglobin complex, to the intracellular iron content of 
monocytes-macrophages, we have investigated if this mechanism plays an 
important role in the determination of the macrophage iron content. Since liver 
and spleen macrophages are not easily accessible in humans and since in vitro 
differentiation of peripheral blood monocytes has been extensively used as a 
model to investigate macrophage development (18), we have studied peripheral 
blood monocytes. We could not detect a difference in the percentage of 
CD163+CD33+ monocytes-macrophages between patients with hereditary 
hemochromatosis and controls or patients with secondary hemochromatosis. 
Since the majority of our patients have serum ferritin concentrations in the 
normal range, due to an adequate phlebotomy treatment, one can argue that the 
CD163 receptor could be only downregulated in situations where iron overload 
is present. However, no correlation between the percentage of CD163+CD33+ 
monocytes-macrophages and serum iron studies is seen. Moreover when 
comparing  hereditary hemochromatosis patients with still elevated serum 
ferritin concentrations and patients with normal serum ferritin concentrations, 
still no difference in percentage of CD163+CD33+ monocytes-macrophages 
could be found. This, again, argues against the influence of elevated serum 
ferritin concentrations on the percentage of CD163+CD33+ monocytes-
macrophages. 
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Moreover in the group of patients with secondary hemochromatosis, although 
serum ferritin concentrations are significantly higher than in controls and 
patients with hereditary hemochromatosis, no difference in the percentage of 
CD163+CD33+ monocytes-macrophages is observed. 
In this subgroup of patients with secondary hemochromatosis, high serum 
ferritin concentrations could be the consequence of inflammation. But only one 
patient in this group has a C-reactive protein concentration higher than normal. 
Also we suspect, that in the presence of inflammation, a low percentage of 
CD163+CD33+ monocytes-macrophages should have been found, which is not 
the case in this patient subgroup.  
Attributing high serum ferritin concentrations to tissue iron overload in the 
group of patients with secondary hemochromatosis, would ideally have required 
the measurement of hepatic iron concentration. We thought however that it was 
unethical to perform a liver biopsy in these patients. On the other hand, it has 
been illustrated that there is a good correlation between serum ferritin 
concentration and tissue iron overload (19).  
 
We conclude that in healthy males, there is no difference in the percentage of 
CD163+CD33+ monocytes-macrophages between the different haptoglobin 
phenotypes. We could not find a difference in the percentage of CD163+CD33+ 
monocytes-macrophages in patients with hereditary or secondary 
hemochromatosis and controls. It seems unlikely that the CD163 receptor 
contributes to the low macrophage iron content seen in patients with hereditary 
hemochromatosis. 
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Table 1. 
Serum iron studies and percentage of CD163+CD33+ monocytes-
macrophages for the total group of healthy male volunteers, patients with 
hereditary and secondary hemochromatosis. 
 
 Healthy 
volunteers 
(n=30) 
Hereditary 
hemochromatosis 
(n=16) 
Secondary 
hemochromatosis  
(n=5) 
Reference 
range 
Serum iron 
(µmol/l) 
21 ± 6 28 ± 14* 25 ± 7 7 - 22 
Serum iron 
saturation (%) 
37 (27-45) 57 (33-95)** 77 (69-85)$ Female <52 
Male <62 
Serum ferritin 
(µg/l) 
131 
(104-198) 
162*** 
(68-370) 
 
2965$$ 
(2325-4195) 
 
36 - 262 
Percentage 
CD163+CD33+ 
monocytes-
macrophages 
54 ± 22 67 ± 23 58 ± 27  
 
Variables with a normal distribution are presented as mean ± standard deviation. 
Variables with a non-Gaussian distribution are presented as median and  
interquartile range.  
* p<0.02 versus control population 
** p<0.01 versus control population  
*** p<0.01 versus patients with secondary hemochromatosis 
$ p<0.01 versus control population 
$$ p<0.01 versus control population 
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Table 2 . 
Serum iron studies, haptoglobin concentration and percentage 
CD163+CD33+ monocytes-macrophages in healthy male volunteers 
according the haptoglobin phenotype. 
 
 Hp 1-1 
(n=6) 
Hp 2-1 
(n=16) 
Hp 2-2 
(n=8) 
Reference 
Range 
Serum iron                                                      
(µmol/l) 
18 ± 6 21 ± 6 20 ± 7 7 - 22 
Serum iron 
Saturation (%) 
32 (28-36) 40 (30-48) 36 (24-48) Female <52 
Male <62 
Serum ferritin 
(µg/l) 
133 (103-231) 163 (114-185) 153 (70-259) 36-262 
Haptoglobin 
concentration 
(g/l)* 
1.23 ± 0.25 0.94 ± 0.27 0.69 ± 0.21 0.38 - 2.27 
Percentage 
CD163+CD33+ 
monocytes-
macrophages 
54 ± 27 53 ± 25 58 ± 18  
 
* p<0.01 (Kruskal-Wallis test). 
Variables with a normal distribution are presented as mean ± standard 
deviation. 
Variables with a non-Gaussian distribution are presented as median and  
interquartile range.  
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Figure 1. 
FACS (fluorescent activated cell sorter) dot plot of CD163+ CD33+ monocytes-
macrophages (right upper quadrant).  
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ABSTRACT 
 
Introduction 
In patients with chronic hepatitis C, elevations in serum iron levels, hepatic iron 
content and oxidative stress-related molecules have been reported. Treatment 
with ribavirin induces an increase in hepatic iron concentration. Since in 
situations of iron overload, non-transferrin bound iron (NTBI) can appear, we 
determined NTBI in untreated chronic hepatitis C patients and in patients during 
interferon-ribavirin treatment.  
Materials and methods 
In 10 untreated and in 19 interferon+ribavirin-treated chronic hepatitis C 
patients, we examined NTBI levels by a colorimetric method using 
nitrilotriacetic acid as a ligand and sodiumtriscarbonatecobalt (III) to block free 
iron binding sites on transferrin. 
Results  
Despite the presence of high serum iron saturation and ferritin levels, NTBI was 
absent in the majority of the HCV patients (25/29, 86 %). There was no 
difference in NTBI levels between untreated and treated patients. Four patients 
with high NTBI levels could be distinguished by higher serum iron levels. In 
two of these patients, hepatocytic iron was present on liver biopsy. 
Discussion 
In the majority of chronic hepatitis C patients, NTBI levels are normal. 
Treatment with ribavirin does not induce high NTBI levels. 
NTBI levels are only higher than normal in hepatitis C patients with higher 
serum iron levels. 
 
Abstract electronic word count: 198 
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Introduction 
Several recent studies have explored the prevalence and significance of elevated 
serum iron levels in chronic hepatitis C virus infection (1). In patients with 
chronic hepatitis C, serum iron is elevated in 27-36 %, transferrin saturation is 
elevated in 18-24 % and serum ferritin is increased in 22-35 %. A strong 
correlation has been observed between serum ferritin and serum AST levels, 
suggesting that release of tissue ferritin from damaged hepatocytes causes the 
elevations in serum iron (2). Others did not find this correlation (3). 
Elevated hepatic iron concentration have been observed in patients with chronic 
hepatitis C, but less frequently than suspected by elevated serum transferrin 
saturation or serum ferritin. The frequency of elevated hepatic iron 
concentration ranges from 10 to 36 % (2,4,5). The elevation in hepatic iron 
content associated with chronic hepatitis C infection is usually mild with a mean 
of hepatic iron index of 0.4-0.6 µmol/g dry liver tissue per year of life (5,6). 
Unlike hepatic iron accumulation in hereditary hemochromatosis, the mild 
hepatic iron overload seen in patients with compensated liver disease does not 
progressively increase over time (7). However, in end-stage  liver disease and 
cirrhosis caused by hepatitis C, hepatic iron index values of more than 1.9 
µmol/g dry liver tissue per life year can be found. Although in this case the 
hepatic iron index is in the range of patients with hereditary hemochromatosis, 
the Cys282Tyr missense mutation is absent (8).  
After interferon treatment, the hepatic iron concentration decreases significantly 
in virological responders and nonresponders. The decrease in stainable liver iron 
is predominantly seen in mesenchymal cells as opposed to hepatocytes (9). This 
leads to the speculation that elevations in hepatic iron seen in chronic viral 
hepatitis are mainly due to phagocytosis of necrotic hepatocytes and 
accumulation of iron in phagocytic cells. 
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On the contrary, increases in hepatic iron concentration have been seen after 
monotherapy with ribavirin. In this case, excess of iron deposits are seen in 
hepatocytes and less in macrophages. Hepatic iron accumulation is well known 
to occur in association with haemolytic disorders. The ribavirin-induced 
haemolysis could be a causal factor in this excess of hepatic iron (10). 
In hepatitis C patients, a pattern of free radical production and lipid peroxidation 
is observed. This correlates with the presence of steatosis and activation of 
gluthatione metabolism, which represents the liver’s physiological scavenging 
response to peroxidative damage (3). The higher serum and tissue iron found in 
patients with chronic hepatitis C, could be the consequence of a local and 
systemic derangement of iron metabolism. 
Non-transferrin-bound iron (NTBI) represents various forms of labile iron 
appearing in the plasma of patients with various pathological conditions (11). 
NTBI is most commonly found in patients whose transferrin iron binding 
capacity has been exceeded by iron overload. NTBI is capable of mediating 
tissue damage by stimulating free radical formation and lipid peroxidation (12). 
As its name indicates, NTBI comprises all forms of iron in the plasma that are 
bound to ligands other than transferrin (13). These ligands are  citrate  (14),  
albumin and perhaps ferritin (15). In a healthy individual the incoming iron 
becomes effectively shie lded from reaction to redox cycling and formation of 
reactive oxygen species by the binding with transferrin (11). Thus, when NTBI 
appears in the plasma, it is believed to result from an imbalance of iron 
metabolism.  
Increased NTBI values are seen in conditions such as: atransferrinemia (11), 
hereditary hemochromatosis (16), haemolytic anaemias (17), end stage renal 
disease on dialysis (18), after chemotherapy (19), during cardiopulmonary 
bypass (20) and in neonates (21). 
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In most of these conditions transferrin is completely saturated, however NTBI is 
also seen in situations where transferrin is not completely saturated (indivi duals 
heterozygous for the hemochromatosis gene (12), in patients on dialysis (18) ...).  
Since in patients with chronic hepatitis C higher serum and hepatic iron levels 
are present, we examined whether NTBI could be one of the factors contributing 
to the increased oxidative stress observed in chronic hepatitis C patients. 
Ribavirin-induced haemolytic anaemia causing a higher liver iron content in 
chronic hepatitis C patients, could also induce the appearance of NTBI.  
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Materials and methods 
Patients 
Ten untreated patients with chronic hepatitis C and 19 patients with chronic 
hepatitis C on treatment with interferon and ribavirin were included in this 
study. The diagnosis of chronic hepatitis C was made on the basis of elevated 
ALT activity (above the upper limit of normal) and the presence of HCV 
antibodies and HCV RNA  in serum. Patients suffering from other chronic liver 
diseases and hepatocellular carcinoma were excluded. The patient characteristics 
are shown in Table 1. 
The patients on treatment received interferon alfa at a dose of 3MU SC thrice 
weekly, while the ribavirin dose was chosen according to the body weight. 
Patients with a body weight less than 75 kg, received 1000 mg of ribavirin per 
day, orally, divided in two doses. Patients weighing more than 75 kg, received a 
dose of ribavirin 1200 mg per day, orally, divided in two doses.  
In untreated patients blood sampling was done at diagnosis. In patients on 
treatment, blood sampling was performed during treatment when they had been 
taken ribavirin for at least 8 weeks. It has been reported that at this moment the 
haemolytic activity of ribavirin is maximal and stable for the rest of the 
treatment (22). 
 
Controls 
In 13 healthy volunteers blood was taken for NTBI measurement. These 
volunteers had no evidence of iron overload or hepatitis C. Informed consent 
was obtained. 
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Biochemical analysis 
Fasting blood samples were obtained, allowed to clot and centrifuged. The 
serum was collected for analysis. 
 
Serum alanine aminotransferase (ALT) activity, serum iron concentration and 
total iron binding capacity (TIBC) were determined using commercial reagents 
on an automated analyser (Roche). 
Transferrin saturation was calculated by the formula: 
   100 x (serum iron/TIBC). 
Serum ferritin concentration was measured using fixed-time immuno-
nephelometry (Dade Behring). 
 
Liver biopsy 
Liver biopsy was performed at diagnosis. Activity and staging were examined 
according the METAVIR scoring system (23). Perls’ stain was performed to 
demonstrate the presence of iron. 
 
HFE missense mutation 
The Cys282Tyr missense mutation was searched for according to the method 
described by Feder et al (24). In short, after extraction of genomic DNA from 
peripheral blood mononuclear cells DNA was amplified by PCR. After 
amplification these fragments were further investigated by restriction enzyme 
digestion followed by agarose gel electrophoresis. The missense mutation 
Cys282Tyr resulted in an additional restriction site for the restriction enzyme 
RsaI. Homozygotes, heterozygotes or normals were easily recognized. Recently, 
a polymorphism in intron 4 of HFE was described causing an overestimation of 
the Cys282Tyr homozygote prevalence in hemochromatosis. We examined all 
samples using a new antisense primer that excluded the site of this new poly-
morphism (25,26). 
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NTBI measurement 
NTBI measurement was done according the method described by Gosriwatana 
et al (27). To prevent displacement of iron from nitrilotriacetic acid (NTA) to 
unsaturated transferrin during this procedure, samples were pretreated with 
triscarbonatecobalt (III).  In short, serum samples were stored frozen at –20° C 
until time of analysis. The samples were thawed by incubation at 37° C for 10 
min.  To serum (450 µl) 100 µl Na3[Co(CO3)3]. 3H2O solution was added and 
the mixture was incubated at 37° C for 1 hour. Subsequently 800 mM 
nitrilotriacetic acid (NTA) was added to the serum mixture to obtain a final 
concentration of 80 mM and allowed to stand for 30 min at room temperature. 
The samples were ultrafiltered using an ultrafilter (Centricon-30) at 3000 g for 1 
h. 
The serum was analysed by using a colorimetric method. The ultrafiltrate was 
diluted 1:1 with 5 mM Mops buffer (pH 7.4) to obtain the volume of 800 µl. To 
form the chromogenic complex, 100 µl of 120 mM thioglycolic acid in 
deionised water and 100 µl of 60 mM bathophenanthroline in deionised water 
were added to the solution and allowed to stand for 30 min. The resulting 
complex was measured by spectrophotometry at 537 nm. 
Despite the use of cobalt in this assay, negative NTBI levels can still be found in 
some samples. Probably this is caused by exchange of transferrin-bound cobalt 
with iron, which is present in 80 mM NTA in standardised small amounts 
(2µM), during the 30 minutes incubation (12).  
 
Statistical analysis  
Statistics were performed using the Medcalc program version 5.00.002 (28). 
Normality of the distribution of the different variables was tested using the 
Kolmogorov-Smirnov test. Variables with a normal distribution are presented as  
mean ± standard deviation. Variables with a non-Gaussian distribution are  
presented as median and  interquartile range.  
 104
Parametric and non-parametric tests were used according the distribution of the 
variable. P-values of < 0.05 were considered significant.  
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Results  
Patient characteristics (Table 1). 
The group of treated patients is younger than the untreated patient group 
(p<0.01). This is also reflected by the higher number of patients infected with 
genotype 3 in the treated population. Not surprisingly patients on treatment have 
lower ALT activity than untreated patients.  
 
Serum iron levels 
Serum iron, serum iron saturation and serum ferritin are not different between 
treated and untreated patients. Twenty-two out of 29 patients (76 %) have serum 
ferritin concentrations above the upper limit of normal (untreated: 7/10 versus 
treated: 15/19, p=NS). A statistically significant correlation is found between 
ALT activity and serum ferritin concentration (r after logarithmic 
transformation=0.39, p=0.03). When treated and untreated patients are 
separately examined, this correlation remains significant in both groups 
(untreated: r=0.70, p=0.02; untreated: r=0.44, p=0.05). 
Three males (19 %) have a serum transferrin saturation exceeding 62 % and 
three females (23 %) have a serum iron transferrin exceeding 52 %. 
 
HFE missense mutation 
The Cys282Tyr missense mutation is found in the heterozygote form in 4 of the 
29 chronic hepatitis C patients. No patient is found to be homozygous for this 
missense mutation. 
There is no difference in serum iron, serum iron saturation and serum ferritin 
levels between heterozygotes and normals.  
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Liver biopsy 
The activity and fibrosis found on liver biopsy are demonstrated in Table 1. 
Only two patients had stainable iron in hepatocytes on the liver biopsy. 
 
Treatment induced haemolysis  
The mean drop in haemoglobin level in the patients receiving interferon-
ribavirin treatment is 2.1 ± 1.1 g/dl . 
 
NTBI values 
NTBI values in the controls (0.29 ± 0.17 µM, range: -0.08 – 0.61) are not 
different from the values found in the hepatitis C patients (0.41 ± 0.44 µM, 
range: -0.31 – 2.05) (Figure 1). The NTBI values found in the control group are 
in accordance with values found by others (12).  
NTBI values in the untreated group are 0.36 ± 0.44 µM. NTBI values in the 
treated group are 0.38 ± 0.29 µM. There is no statistical difference between the 
two groups (Figure 2).  
In Cys282Tyr heterozygotes, NTBI values are not higher than in patients with 
the wild type (0.21 ± 0.12 µM versus 0.44 ± 0.47 µM). 
There is no correlation between NTBI values and ALT activity, serum 
transferrin saturation, serum ferritin concentration and activity or fibrosis on 
liver biopsy. 
Although the hepatitis C group has no higher NTBI values than the control 
group, 4 patients have NTBI values which are higher than the controls. 
These patients will be briefly described. 
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Patient 1 
Patient 1 is a 56 year old man ( untreated group) of Egyptian origin. He has 
probably been infected during childhood during a prevention programme against 
Schistosomiasis. The infecting genotype is 4. Serum iron concentration is 50 
µmol/l, serum iron saturation 96% and serum ferritin concentration 1920 µg/l. 
NTBI is present at a value of 2.05 µM. ALT activity is 199 U/l. Metavir score 
for the liver biopsy is: activity grade 2 and fibrosis stage 4. Perls’staining 
demonstrates iron deposits in several hepatocytes. The Cys282Tyr missense 
mutation is absent in this patient, he has no family history suggestive for 
hereditary hemochromatosis and there is no evidence for secondary iron 
overload disease. 
 
Patient 2 
Patient 2 is a 43 year old man (treated group) of Belgian origin. He has been 
infected with the hepatitis C virus genotype 3 through intravenous drug abuse. 
ALT activity at the moment of blood sampling is 31 U/L. Serum iron 
concentration is 32 µmol/l, serum iron saturation is 72 % and serum ferritin 
concentration is 350 µg/l. NTBI is present at a value of 0.89 µM. Metavir score 
for the liver biopsy is: activity grade 3 and fibrosis stage 3. Perls’ staining 
demonstrates iron deposits in several hepatocytes. The Cys282Tyr missense 
mutation is absent, he has no family history suggestive for hereditary 
hemochromatosis and there is no evidence for secondary iron overload disease. 
 
Patient 3 
Patient 3 is a 39 year old man (treated group) infected with the hepatitis C virus 
of genotype 1b. The route of transmission is unknown. ALT activity is 90 U/L. 
Serum iron concentration is 28 µmol/l, serum iron saturation is 54% and serum 
ferritin concentration is 1120 µg/l. NTBI is present at a value of 0.81 µM.  
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Metavir score for the liver biopsy is: activity grade 3 and fibrose stage 3. 
No iron deposits are found in the liver biopsy. The Cys282Tyr missense 
mutation is absent, there is no evidence for hereditary or secondary 
hemochromatosis.  
 
Patient 4 
Patient 4 is a 34 year old man (treated group) infected with the hepatitis C virus 
of genotype 3 through intravenous drug abuse. ALT activity is 23 U/L. Serum 
iron concentration is 28 µmol/l, serum iron saturation is 58 % and serum ferritin 
concentration is 348 µg/l. NTBI is present at a value of 0.93 µM. Metavir score 
for the liver biopsy is: activity grade 1 and fibrosis stage 1. No iron deposits are 
found in the liver biopsy. The Cys282Tyr missense mutation is absent, there is 
no evidence for hereditary nor secondary hemochromatosis.  
 
When these four patients are compared to the other patients, higher serum iron, 
serum iron saturation and serum ferritin concentrations are found ( Table 2). The 
two patients with the highest serum iron saturation, are the only two patients 
with stainable iron on liver biopsy. 
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Discussion 
Patients with chronic hepatitis C often have elevated serum iron studies (1). In 
our series of 29 patients 22 (76 %) have elevated serum ferritin concentrations. 
A significant correlation is found between serum ferritin concentration and 
serum ALT activity. This suggests, as published by others (2,3), that the release 
of  ferritin from damaged hepatocytes is, at least partly, responsible for the 
elevations in serum ferritin levels. However the correlation is more significant in 
untreated patients than in treated patients. This can be explained by the capacity 
of ribavirin to induce normal ALT activity despite ongoing hepatoinflammatory 
activity (29).  
Although none of the patients is homozygous for the Cys282Tyr missense 
mutation, 19 % of the male patients and 23 % of the female patients have serum 
iron saturation levels in the range that is suggestive for hereditary 
hemochromatosis.  
Several authors have demonstrated the presence of oxidative stress in patients 
with chronic hepatitis C (3). Considering the high serum iron concentrations and 
the presence of oxidative stress, it is tempting to look for NTBI. Since NTBI is 
likely a factor to contribute to oxidative stress (3), we have investigated the 
presence of NTBI in chronic hepatitis C patients.  
Despite the presence of elevated serum iron indices in a substantial number of 
our patients, we have found that in the majority of the patients with chronic 
hepatitis C,  NTBI values are normal.  However in 4 out of 29 patients (14 %), 
high NTBI values are found. Similar percentages of elevated NTBI values are  
found in patients with end stage renal disease, in neonates and during 
cardiopulmonary bypass. However in these conditions reported levels are 
generally in the range from 1 to 10 µM (11) which is higher than those observed 
in our patient group.   
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In the 4 patients with high NTBI values, serum iron, serum iron saturation and 
serum ferritin concentration are higher than in the rest of the patients. 
In these 4 patients hereditary and secondary hemochromatosis have been 
excluded. Although it is possible that other genetic mutations causing iron 
overload are present, this hypothesis seems less likely, considering the absence 
of a positive family history for iron overload.  
In 2 of these 4 patients iron deposits are observed in the hepatocytes. This is not 
surprising, since it has been demonstrated that hepatocytes have the possibility 
to take up free iron (30). The presence of NTBI in chronic hepatitis C could be a 
hallmark of tissue iron overload. However this needs confirmation by comparing 
the hepatic iron concentration in the presence and absence of NTBI.  
In healthy individuals heterozygous for the Cys282Tyr missense mutation, 
higher NTBI values are detected (12). However in our chronic hepatitis C 
patient group, no difference could be found between NTBI values in the four 
heterozygotes and normals.  
Treatment of chronic hepatitis C with ribavirin causes haemolytic anaemia in a 
substantial portion of the patients. In ribavirin treated patients, iron deposits in 
the hepatocytes and increases in hepatic iron concentrations have been 
demonstrated (10). Hepatic iron accumulation is well known to occur in 
association with other chronic haemolytic conditions. Iron released by 
haemolysis would be expected to accumulate in the reticuloendothelial system. 
However increased iron staining is noted in both the cells of the 
reticuloendothelial system and in hepatocytes. The deposition of iron in 
hepatocytes suggests that the mechanism of iron loading is enhanced mucosal 
absorption associated with accelerated erythropoiesis (10). 
We have failed to demonstrate higher NTBI values in the group of treated 
patients. They all had substantial haemolysis as demonstrated by the drop in 
haemoglobin level during the treatment. Interferon in monotherapy decreases 
hepatic iron concentra tion and iron deposits in the mesenchymal cells (9).  
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Combining interferon with ribavirin in the treatment of chronic hepatitis C, 
could counteract the ribavirin induced increases in hepatic iron concentration. 
However, this seems unlikely since a) ribavirin induced haemolytic anaemia 
remains present in the combination treatment and b) iron deposits caused by 
ribavirin are mainly seen in the hepatocytes and less in the macrophages (10). 
We have not performed control biopsies during or immediately after the 
treatment. Therefore we have not been able to look for the presence of excess of 
iron in the control biopsy. 
A longitudinal study of a group of patients treated with the combination 
treatment should be performed to definitely exclude the occurrence of NTBI 
during treatment.  
 
We conclude that in the majority of chronic hepatitis C patients, despite the 
presence of high serum iron indices, NTBI values are not different from 
controls. In the few cases where NTBI values are higher than in controls, higher 
serum iron concentration, serum iron saturation and serum ferritin concentration 
are observed.  
Despite the presence of haemolytic anaemia, treatment with ribavirin does not 
result in higher NTBI levels.  
Further studies (longitudinal follow up studies of chronic hepatitis C patients 
before, during and after treatment and comparison with hepatic iron 
concentration) are necessary to give a more detailed view of the importance of 
NTBI in chronic hepatitis C.  
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Table 1. 
Patient characteristics 
 
 
 Untreated patients 
(n=10) 
Treated patients 
(n=19) 
Reference range 
Gender (male/female) 5/5 11/8  
Age (years) * 50 ±  7 38 ±  11  
ALT activity(U/l) * 114 ±  72 31 ±  30 7 - 31 
Serum iron (µmol/l) 27 ±  9 22 ±  9 7 - 22 
Serum iron saturation (%) 38 (31-51) 37 (23-55) Female <52 
Male <62 
Serum ferritin concentration (µg/l) 292 (121-390) 318 (211-430) 36 - 262 
Liver biopsy 
   Activity scale (n): 1 
                                 2 
                                 3 
 
   Fibrosis scale (n) :  0 
                                   1 
                                   2 
                                   3 
                                   4 
 
5 
5 
 
 
1 
2 
3 
1 
3 
 
7 
6 
6 
 
0 
8 
5 
5 
1 
 
   Genotype (n)    1a 
                            1b 
                            3 
                            4 
                            unknown 
1 
8 
 
1 
2 
7 
8 
1 
1 
 
HFE missense mutation (n) 
  Cys282Tyr -/- 
  Cys282Tyr +/-   
 
8 
2 
 
17 
2 
 
 
*  p<0.01 
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Table 2. 
Serum iron, iron saturation and ferritin concentration in chronic hepatitis 
C patients with higher than normal NTBI levels (left) and normal NTBI 
levels (right). 
 
 
 ‘High’ NTBI levels 
(n=4) 
‘Normal’ NTBI 
levels (n=25) 
Reference 
range 
p-value 
Serum iron 
(µmol/l) 
35 ± 10 22 ± 8 7 – 22 <0.001 
Serum iron 
saturation (%) 
65 (56-84) 36 (24-41) Female <52 
Male <62 
<0.001 
Serum ferritin 
concentration 
(µg/l) 
735 (349-1520) 284 (120-390) 36-262 0.02 
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Figure 1. 
NTBI values in the controls (left) and in patients with chronic hepatitis C 
(right). 
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Figure 2. 
NTBI values in untreated (left) and treated (right) chronic hepatitis C 
patients. 
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GENERAL DISCUSSION 
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The HFE mutation and the haptoglobin polymorphism both influence iron 
storage capacity (1,2) and are related with different immunological properties 
(3). 
The HFE mutation is found in the majority of patients with hereditary 
hemochromatosis (4). Convincing data are available demonstrating that this 
gene is not just an innocent bystander, but really contributes to tissue iron 
overload (5-11). In the presence of tissue iron overload and the HFE 
mutation, different perturbations in the immune status of hereditary 
hemochromatosis patients have been reported (3).  
 
Haptoglobin is a protein with haemoglobin-binding capacity and prevents 
iron loss and kidney damage during periods of haemolysis. The three major 
haptoglobin phenotypes have different effects on cellular and humoral 
immune responses (12). Individuals with the Hp 2-2 phenotype carry higher 
numbers of CD4+ T-lymphocytes and B-lymphocytes (13). Hp 2-2 also 
displays higher agglutination capacities against some bacteria (12). 
Healthy male individuals with the Hp 2-2 phenotype have higher levels of 
both serum and monocyte ferritin than individuals with the Hp 2-1 or 1-1 
phenotype (14). 
 
Since both hereditary hemochromatosis and chronic hepatitis C infection are 
associated with higher serum and tissue iron stores and with differences in 
immune status, we examined the influence of the HFE mutation and the Hp  
polymorphism on both diseases. 
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Hereditary hemochromatosis is the most frequent genetically determined iron 
storage disease in Western Europe (15). Before the discovery of the 
hemochromatosis gene in 1996 by Feder et al (4), clinicians had to rely on 
phenotypic characteristics of the disease (e.g. serum iron saturation, serum 
ferritin level, hepatic iron index, hereditary character ...) to establish the 
diagnosis. Since the detection of the HFE  mutation, diagnosis in a single 
patient, family screening and in a certain way, population screening have 
become easier.  
Since more patients with hereditary hemochromatosis are diagnosed, it has 
become obvious that not all subjects homozygous for the Cys282Tyr 
missense mutation have the typical phenotypic characteristics of patients 
with hereditary hemochromatosis (16,17). Moreover other missense 
mutations (e.g. His63Asp) could play a role in iron overload disorders in 
patients not homozygous for the Cys282Tyr missense mutation. 
 
In Chapter I, we determined the Cys282Tyr and the His63Asp missense 
mutation in a cohort of patients displaying the phenotype of hereditary 
hemochromatosis and in group of healthy controls. The patients were 
followed in the out-patient clinic between 1985 and 1997 (18). In the healthy 
control group 10.5 % of the 96 studied subjects were heterozygous for the 
Cys282Tyr missense mutation and 2 % were homozygous for this missense 
mutation. Of the 49 patients, 46 (94 %) were homozygous for the Cys282Tyr 
missense mutation; 2 were compound heterozygous (Cys282Tyr +/-, 
His63Asp +/-) and one patient was only heterozygous for the His63Asp 
missense mutation. These results are in accordance with the reported 
prevalences in other countries and confirm that the Cys282Tyr missense 
mutation in the HFE gene is present in a majority of patients with hereditary 
hemochromatosis and contributes to the phenotypic expression of the disease 
(4). 
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The significance of the His63Asp mutation is less clear. It is suggested that it 
is only of importance in the compound heterozygote setting. In our patient 
group, the 2 patients who are compound heterozygotes have the clinical 
picture of hereditary hemochromatosis. The identification of one patient with 
hemochromatosis which is only heterozygous for the His63Asp mutation 
suggests the existence of other genetic (or non-genetic) causes. 
 
Since in healthy subjects the Hp 2-2 phenotype is associated with higher 
serum ferritin and monocyte ferritin content (14), we have investigated in 
Chapter II, the influence of the Hp polymorphism on the phenotypic 
presentation of 167 patients with hereditary hemochromatosis. A low Hp1 
allele frequency is found and is attributable to an overrepresentation of the 
Hp 2-2 phenotype (p<0.01). Hp 2-2 is associated with a relative risk of 1.73 
(95 % CI 1.14-2.62) for hemochromatosis. The underrepresentation of the 
Hp1 allele is only observed in the male patients (p<0.01) but is not 
significant in the female patients (p=0.3). In the male population serum iron 
levels, serum ferritin levels and the amount of iron removed by phlebotomy 
to achieve iron depletion, are higher in hemochromatosis patients carrying 
the Hp 2-2 phenotype. The absence of similar findings in females is possibly 
related to the lower number of females included, although other factors (e.g. 
menstruation, pregnancy) could have a greater influence on the phenotypic 
expression of hereditary hemochromatosis in female patients (19). 
 
The higher levels of serum ferritin both in Hp 2-2 healthy men and in Hp 2-2 
male hemochromatosis patients could be explained by the Hp 2-2 specific 
transfer of Hb-Hp complexes into monocytes-macrophages. The Hb-Hp 
related iron uptake in monocytes-macrophages has recently been 
demonstrated to occur via the Hb scavenger receptor CD163. 
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This receptor has a higher affinity for the multimeric Hb-Hp 2-2 complex 
than for the monomeric Hb-Hp 1-1 complex (20). Since the CD163 receptor 
could play a role in the iron status of healthy subjects and patients with 
hereditary hemochromatosis, we examined the percentage of CD163 positive 
monocytes-macrophages in both populations (Chapter III). In the control 
group of 30 male healthy volunteers there is neither difference in the 
percentage of CD163 positive monocytes-macrophages between the different 
haptoglobin phenotypes nor any correlation between the CD163 receptors 
and serum iron indices. 
 
In patients with hereditary hemochromatosis, we found no different 
percentage of CD163 positive monocytes-macrophages than in patients with 
secondary hemochromatosis or in controls. It seems unlikely that the low 
macrophage iron content seen in  patients with hereditary hemochromatosis 
is influenced by a different percentage of CD163+ monocytes-macrophages. 
 
The prevalence of chronic hepatitis C infection in the Belgian population is 
0.9 % (21). Chronic hepatitis C virus infection is associated with iron 
overload and increased oxidative stress (22). Both viral factors (genotype, 
viral load) and/or host factors (immune response) seem to influence the 
outcome of a hepatitis C virus infection. In Chapter IV we have 
demonstrated that both the Cys282Tyr missense mutation and the Hp 1-1 
phenotype are overrepresented in a group of 142 chronic hepatitis C patients 
(23). Remarkably, the presence or absence of one gene seems to determine 
the impact of the other gene on the risk to develop chronic hepatitis C virus 
infection. More precisely, in the absence of the Cys282Tyr missense 
mutation, the Hp phenotype determines the risk to develop a chronic hepatitis 
C infection. Only in this group of patients, a significant overrepresentation of 
the Hp 1-1 phenotype is found. 
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In addition we see a significant higher Cys282Tyr allele frequency in the 
group of patients with the Hp 2-1 and 2-2 phenotype. We assume that the 
higher oxidative stress that could be present in individuals with both the 
Cys282Tyr allele and the Hp2 allele results in a higher risk in this subgroup 
to develop a chronic hepatitis C infection. 
Since we have not followed our patient group for a time period and our study 
is only a single time point measurement, it is difficult to comment on 
progression of the disease. However, since we have found an 
overrepresentation of the Hp 1-1 phenotype in our group of patients with 
chronic hepatitis C, we make the assumption that the presence of this 
phenotype makes the infected patient more susceptible to develop a chronic 
infection. To strengthen this assumption, it should be interesting to look for a 
patient group with acute hepatitis C. In this group of patients, a difference in 
haptoglobin phenotype distribution should be looked for between the group 
of patients with a self-resolving hepatitis C and the group of patients that 
progresses to chronicity. However, for practical reasons, this is very difficult 
since acute hepatitis C is mostly asymptomatic, the number of patients with 
acute hepatitis C is very low (approximately 30 registered acute hepatitis C 
patients annually in Belgium) and since a recent study by Jaeckel et al (24), it 
is not ethical any more to deny patients with an acute hepatitis C a treatment 
with interferon alfa. 
 
Together with interferon alfa, ribavirin has become the standard treatment of 
chronic hepatitis C infection (25,26). Ribavirin treatment induces higher 
serum and liver iron levels, probably due to the haemolytic anaemia it causes 
(27,28). Because little is known about the host, viral and treatment factors 
that may influence ribavirin-induced haemolysis, we have examined in 
Chapter V several factors that could influence the drop in haemoglobin level 
during treatment with interferon and ribavirin (29). 
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We have demonstrated that the degree of haemoglobin loss is higher in 
patients with a higher pre-treatment haemoglobin level, with a low number of 
platelets, during daily administration of interferon-alfa, and in the presence of 
the Hp 1-1 phenotype. 
The correlation between the pre-treatment haemoglobin level and the drop in 
haemoglobin can be explained by the fact that ribavirin-induced haemolysis 
breaks down a certain proportion of the available erythrocytes pool. Higher 
absolute drops in the haemoglobin level will therefore be observed in 
subjects with the higher pre-treatment haemoglobin levels. 
Patients with lower platelet counts (<110,000/µl) have a significantly higher 
drop in haemoglobin level than those with higher counts. The low pre-
treatment platelet count can be considered as a hallmark of the presence of 
liver cirrhosis with hypersplenism. 
Patients receiving a higher dose of  interferon-alfa experience a higher drop 
in haemoglobin level than those patients receiving a standard dose. 
Interferon-alfa is known to be myelosuppressive and by itself a cause of 
anaemia, especially when given in higher doses. 
Patients with the Hp 1-1 phenotype experience a higher drop in haemoglobin 
level during interferon-ribavirin treatment. Complexes of haemoglobin and 
dimeric haptoglobin (Hp 1-1) exhibit lower functional affinity for the CD163 
receptor than do complexes of haemoglobin and the multimeric Hp 2-2 
haptoglobin (20). In situations of haemolysis, this could result in less 
adequate re-utilisation of haem-iron and a higher degree of drop in 
haemoglobin. 
 
Several recent studies have demonstrated that serum iron indices and liver 
iron content are frequently elevated in patients with chronic hepatitis C (30). 
Also, a pattern of free radical production and lipid peroxidation is observed 
(22). 
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This could be the consequence of a local and systemic derangement of iron 
metabolism. Since NTBI is likely to be one of the several factors responsible 
for oxidative stress in situations with iron overload, we investigated in 
Chapter VI if NTBI is present in patients with chronic hepatitis C. In the 
majority of the patients (86 %) we cannot demonstrate the presence of NTBI. 
Even during a treatment with interferon and ribavirin where haemolysis 
contributes to higher serum iron indices and liver iron content, NTBI values 
cannot be detected. In the few patients where NTBI is high, it could be a 
hallmark of real iron overload. 
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GENERAL CONCLUSION 
 
We could demonstrate that the Hp polymorphism affects the iron metabolism 
in  patients with hereditary hemochromatosis and influences the evolution to 
chronicity in patients with hepatitis C virus infection. The Hp  polymorphism 
also influences the degree of haemolysis during a treatment with interferon-
alfa and ribavirin. This results in the clinical implication that in patients with 
chronic hepatitis C and low platelets, a high dose interferon treatment results 
in a higher degree of haemolysis in patients with the Hp 1-1 phenotype. 
Therefore high dose interferon treatment should be avoided in this subgroup 
of patients. 
The percentage of CD163 positive monocytes-macrophages is not influenced 
by the Hp phenotype. It seems unlikely that the low macrophage iron content 
seen in patients with hereditary hemochromatosis is influenced by a different 
percentage of CD163+ monocytes-macrophages.  
Despite the fact that serum and liver iron content are often higher than 
normal in patients with chronic hepatitis C, the majority of the investigated 
patients have no detectable NTBI. However in a minority of these patients 
elevated NTBI levels are found. Further research will focus on the correlation 
between the presence or absence of NTBI, haptoglobin phenotype 
polymorphism and HII, the influence of the presence of NTBI on response 
after antiviral treatment and the possible influence of phlebotomy in patients 
with high NTBI on response after antiviral treatment. 
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Zowel de HFE mutatie als het haptoglobine polymorfisme beïnvloeden het 
ijzermetabolisme (1,2) en houden verband met verschillende 
immunologische eigenschappen (3). 
De HFE mutatie wordt teruggevonden bij de meerderheid van de patiënten 
met erfelijke hemochromatose (4). Er zijn overtuigende gegevens 
voorhanden dat deze mutatie werkelijk bijdraagt tot de overmaat aan 
ijzeropstapeling, eigen aan deze ziekte (5-11). In situaties waar er een teveel 
aan weefselijzer aanwezig is, ziet men in de aanwezigheid van de HFE 
mutatie diverse wijzigingen in de immuunstatus van patiënten met erfelijke 
hemochromatose ontstaan (3).  
Haptoglobine is een eiwit dat hemoglobine bindt en daardoor ijzerverlies en 
nierbeschadiging voorkomt tijdens episodes van hemolyse. De drie 
belangrijkste haptoglobine fenotypes hebben elk een verschillend effect op 
de cellulaire en humorale immuunrespons (12). Bij individuen met het Hp 2-
2 fenotype vindt men een hoger aantal CD4+ T-lymfocyten en B-lymfocyten 
(13). Het Hp 2-2 eiwit vertoont een hogere agglutinatiecapaciteit tegen 
bepaalde bacteriën dan de andere fenotypes (12). Bij gezonde mannen met 
het Hp 2-2 fenotype vindt men zowel een hogere serum ferritine concentratie 
als een hoger ferritine gehalte in monocyten terug dan bij mannen met het Hp 
2-1 of Hp 1-1 fenotype (14). 
Gezien erfelijke hemochromatose en chronische hepatitis C infectie 
geassocieerd zijn met zowel hoog serum en weefselijzer als met verschillen 
in immuun status, onderzochten we de invloed van de HFE mutatie en het 
haptoglobine polymorfisme op deze twee aandoeningen. 
In West-Europa is erfelijke hemochromatose de meeste frequente erfelijke 
aandoening met invloed op het ijzermetabolisme (15).  
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Vooraleer de groep van Feder (4) in 1996 de hemochromatosemutatie 
ontdekte, waren de fenotypische karakteristieken van de aandoening (vb. 
serum ijzersaturatie, serum ferritine concentratie, hepatische ijzerindex, 
erfelijk karakter …) de belangrijkste aanknopingspunten voor de clinicus om 
de diagnose te stellen. Actueel worden, dankzij de ontdekking van de HFE 
mutatie, diagnosestelling, familiescreening en populatiescreening eenvoudig. 
Het werd dan ook duidelijk dat niet alle individuen die homozygoot zijn voor 
de Cys282Tyr missense mutatie, de typische fenotypische karakteristieken 
hebben van erfelijke hemochromatose (16,17). In de afwezigheid van 
Cys282Tyr homozygotisme zouden ook andere mutaties (vb. His63Asp) een 
rol kunnen spelen in de etiologie van ijzeropstapelingsziekten. Bij een 
controlegroep en bij een groep van patiënten met de fenotypische 
karaktertrekken van erfelijke hemochromatose bepaalden we de aan- of 
afwezigheid van de Cys282Tyr en His63Asp missense mutatie (Hoofdstuk 
I). De patiënten werden ambulant gevolgd in de periode 1985-1997 (18). In 
de gezonde controlegroep waren 10,5 % van de 96 individuen heterozygoot 
voor de Cys282Tyr missense mutatie. Twee procent van hen was 
homozygoot voor deze mutatie. In de patiëntengroep waren er 46 van de 49 
patiënten (94 %) homozygoot voor de Cys282Tyr missense mutatie; 2 waren 
compound heterozygoot (Cys282Tyr +/-, His63Asp +/-) en 1 individu was 
enkel heterozygoot voor de His63Asp missense mutatie. Deze resultaten zijn 
perfect te vergelijken met de prevalenties teruggevonden in andere studies en 
landen. Ze bevestigen ook dat de Cys282Tyr missense mutatie 
teruggevonden wordt bij de meerderheid van patiënten met erfelijke 
hemochromatose en dat deze mutatie zou kunnen bijdragen tot de 
fenotypische expressie van deze ziekte (4). Of de His63Asp missense mutatie 
ook bijdraagt tot deze fenotypische expressie is ver van duidelijk. 
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Deze mutatie lijkt enkel belangrijk te zijn wanneer ze samen voorkomt met 
de Cys282Tyr missense mutatie (compound heterozygotisme). We vonden 
deze toestand terug bij twee patiënten van onze groep; beiden hadden de 
fenotypische presentatie passend bij erfelijke hemochromatose. De 
identificatie van 1 patiënt met fenotypische hemochromatose maar enkel 
heterozygoot voor de His63Asp missense mutatie, suggereert het bestaan van 
andere genetische of niet genetische oorzaken. 
 
Bij gezonde mannelijke vrijwilligers met het Hp 2-2 fenotype vond men 
hogere serum ferritineconcentraties en een hogere ferritine inhoud in 
monocyten terug (14). We onderzochten daarom in Hoofdstuk II, de invloed 
van het Hp polymorfisme op de fenotypische presentatie van 167 patiënten 
met erfelijke hemochromatose. Een significante lage Hp1 allel frequentie 
tengevolge van een Hp 2-2 fenotype overrepresentatie (p<0,01) werd 
teruggevonden. De aanwezigheid van het Hp 2-2 fenotype induceert een 
relatief risico van 1,73 (95 % CI 1,14-2.62) tot het ontwikkelen van erfelijke 
hemochromatose. De lage Hp1 allel frequentie vond men enkel terug bij 
mannen (p<0,01), maar niet bij vrouwen (p=0,3). Bij Hp 2-2 mannen werd 
een hogere serum ijzerconcentratie, serum ferritineconcentratie en aantal 
aderlatingen tot ijzerdepletie teruggevonden. Het laag aantal vrouwelijke 
patiënten geïncludeerd in deze studie zou het ontbreken van significantie in 
deze subgroep kunnen verklaren. Evenmin is het uitgesloten dat andere 
factoren (menstruatie, zwangerschap) een grotere invloed hebben op de 
fenotypische expressie van erfelijke hemochromatose (19).  
De hogere serum ferritine concentraties, zowel bij gezonde mannen als bij 
mannelijke hemochromatosepatiënten zou kunnen verklaard worden door het 
Hp 2-2 specifiek transfer van hemoglobine-haptoglobine complexen in 
monocyten-macrofagen. 
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Recent werd aangetoond dat het hemoglobine-haptoglobine complex, en het 
daarmee gerelateerde ijzer, opgenomen wordt in monocyten-macrofagen via 
de CD163 receptor op deze cellen. Deze receptor heeft een hogere affiniteit 
voor Hb-Hp 2-2 complexen dan voor Hb-Hp 1-1 complexen (20). Zowel bij 
gezonden als bij patiënten met erfelijke hemochromatose zou deze CD163 
receptor een rol kunnen spelen in de ijzerstatus van het individu. We 
bepaalden daarom het percentage CD163 positieve monocyten-macrofagen 
bij gezonden en bij patiënten met erfelijke hemochromatose (Hoofdstuk III). 
Bij de gezonde controlegroep vonden we geen haptoglobine-gerelateerd 
verschil in het percentage CD163 positieve monocyten-macrofagen. Evenmin 
was er een correlatie tussen het percentage CD163 positieve monocyten-
macrofagen en serum ijzerparameters.  
Er werd geen verschil opgemerkt tussen het percentage CD163+ monocyten-
macrofagen tussen patiënten met erfelijke hemochromatose en patiënten met 
secundaire hemochromatose of individuen uit de controlepopulatie. Het lijkt 
daarom zeer onwaarschijnlijk dat de lage ijzerinhoud van macrofagen bij 
patiënten met erfelijke hemochromatose beïnvloed wordt door een verschil in 
percentage aan CD163+ monocyten-macrofagen. 
 
In België bedraagt de prevalentie van chronische hepatitis C infectie 0,9 % 
(21). Bij een chronische hepatitis C infectie vindt men vaak een overmaat aan 
ijzer en verhoogde oxidatieve stress (22). Zowel virale (genotype, 
hoeveelheid virus) als gastheerfactoren (immuunantwoord) beïnvloeden het 
verloop van de hepatitis C infectie. 
 
In Hoofdstuk IV toonden we aan dat bij een groep van 142 chronische 
hepatitis C patiënten, zowel de Cys282Tyr missense mutatie als het Hp 1-1 
fenotype in een statistisch hoger frequentie aanwezig zijn dan bij een 
controlepopulatie (23). Heel opvallend blijkt de aan- of afwezigheid van het 
ene gen, de impact van het andere gen te beïnvloeden. 
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Zo blijkt enerzijds, dat bij de afwezigheid van de Cys282Tyr missense 
mutatie, het Hp fenotype bepalend is voor het risico tot het ontwikkelen van 
een chronische hepatitis C infectie. Enkel in deze subgroep van patiënten 
zien we een hogere frequentie van het Hp 1-1 fenotype. Anderzijds ziet men 
een hogere frequentie van de Cys282Tyr missense mutatie in de groep van 
patiënten met het Hp 2-1 en Hp 2-2 fenotype. We veronderstellen dat de 
verhoogde oxidatieve stress aanwezig in de patiënten met zowel het 
Cys282Tyr allel als het Hp2 allel, resulteert in een hogere risico in deze 
subgroep om een chronische hepatitis C infectie te ontwikkelen.  
Omdat we patiënten niet over een tijdspanne gevolgd hebben, maar dat deze 
observatie enkel een momentopname betreft, is het moeilijk commentaar te 
geven over de ziekteprogressie. Echter omdat we een significante 
overrepresentatie vinden van het Hp 1-1 fenotype bij deze groep van 
patiënten met een chronische hepatitis C infectie, maken we de 
veronderstelling dat de aanwezigheid van dit fenotype de patiënt gevoeliger 
maakt voor het ontwikkelen van een chronische hepatitis C infectie. Om dit 
te kunnen staven, is er interesse in een studie bij patiënten met een acute 
hepatitis C infectie, waarbij gepoogd wordt een verschil in haptoglobine 
fenotypedistributie aan te tonen tussen de groep met een zelflimiterende 
infectie en de groep welke evolueert naar een chronische hepatitis C. Dit is 
praktisch echter niet haalbaar omdat de meerderheid van de patiënten met 
een acute hepatitis C infectie asymptomatisch zijn, het aantal gerapporteerde 
acute hepatitis C infecties laag is (ongeveer 30 geregistreerde acute hepatitis 
C gevallen in België per jaar) en het sinds de studie van Jaeckel et al (24) niet 
ethisch meer is een patiënt met een acute hepatitis C infectie een behandeling 
met interferon alfa te ontzeggen. 
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Ribavirine, in combinatie met interferon alfa, is de standaardbehandeling van 
patiënten met chronische hepatitis C infectie (25,26). 
Ribavirine veroorzaakt hemolyse, waardoor een stijging in serum ijzer en 
ijzerinhoud van de lever wordt waargenomen (27,28). Er is weinig gekend 
over factoren die deze hemolyse kunnen beïnvloeden. Wij onderzochten 
daarom in Hoofdstuk V, welke factoren de hemoglobinedaling kunnen 
beïnvloeden gedurende een behandeling met interferon en ribavirine (29). 
We konden aantonen dat een ernstiger hemoglobinedaling werd geobserveerd 
bij patiënten met een hoger hemoglobinegehalte bij het opstarten van de 
behandeling, een laag aantal trombocyten, dagelijkse toediening van 
interferon alfa en de aanwezigheid van het Hp 1-1 fenotype. 
Omdat ribavirine een zekere, relatieve constante, proportie van de aanwezige 
rode bloedcellen afbreekt ziet men een correlatie tussen het 
hemoglobinegehalte bij het opstarten en de hemoglobinedaling gedurende de 
behandeling. Daardoor resulteren hogere startwaarden van hemoglobine in 
een hogere absolute daling van het hemoglobinegehalte. 
Bij patiënten met lagere trombocyten (<110.000/µl) ziet men een 
belangrijkere hemoglobinedaling dan bij patiënten met trombocytenaantallen 
die hoger zijn. Het laag aantal trombocyten wordt beschouwd als een 
handtekening van de aanwezigheid van levercirrose met hypersplenisme. 
Patiënten die een hogere dosis interferon alfa toegediend krijgen (onder de 
vorm van een dagelijkse toediening), ondervinden ook een hogere 
hemoglobinedaling dan de patiënten die een standaard dosis interferon 
krijgen (drie keer per week). Het is immers gekend dat interferon alfa 
myelosuppressief werkt en, vooral wanneer toegediend in een hoge dosis, 
anemie kan veroorzaken. 
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Patiënten met het Hp 1-1 fenotype ondervinden eveneens een hogere 
hemoglobinedaling dan patiënten met de andere fenotypes. Hb-Hp 1-1 
complexen hebben een lagere affiniteit voor de CD163 receptor dan Hb-Hp 
2-2 complexen (20). In geval van hemolyse kan dit leiden naar een minder 
adequaat hergebruik van heemijzer en een belangrijker daling in het 
hemoglobinegehalte. 
Bij patiënten met chronische hepatitis C infectie vindt men frequent 
verhoogde serumijzer-waarden en een hogere ijzerinhoud in de lever terug 
(30). Daarnaast observeert men eveneens situaties die gepaard gaan met 
vrijstelling van vrije radicalen en vetperoxidatie (22). Dit zou kunnen het 
gevolg zijn van een lokaal of systemische stoornis in het ijzermetabolisme. 
Omdat NTBI één van de factoren is die verantwoordelijk kan gesteld worden 
voor oxidatieve stress in situaties met overmaat aan ijzer, onderzochten we in 
Hoofdstuk VI, de aanwezigheid van NTBI bij patiënten met chronische 
hepatitis C infectie. In de meerderheid van hen (86 %) werd geen NTBI 
aangetroffen. Evenmin werd gedurende een behandeling met interferon en 
ribavirine NTBI aangetroffen. Bij de zeldzame patiënt waar NTBI wel 
aangetroffen wordt, kan dit een handtekening zijn van echte overmaat in 
weefselijzer. 
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ALGEMEEN BESLUIT 
 
We konden aantonen dat het Hp fenotype het ijzermetabolisme van patiënten 
met erfelijke hemochromatose en de evolutie naar chroniciteit bij patiënten 
met een chronische hepatitis C infectie beïnvloedt. Het Hp fenotype 
beïnvloedt ook de graad van hemolyse gedurende een behandeling met 
interferon alfa en ribavirine. Klinisch betekent dit dat een behandeling met 
hoog gedoseerde interferon bij een patiënt met lage plaatjes en het Hp 1-1 
fenotype resulteert in een belangrijker graad van anemie. Hoog gedoseerde 
interferonbehandeling moet dan ook vermeden worden in deze subgroep van 
patiënten. 
Bij een gezonde mannelijke controlepopulatie wordt het percentage CD163 
positieve monocyten-macrofagen niet beïnvloed door het Hp fenotype. Het 
lijkt onwaarschijnlijk dat de lage ijzerinhoud van macrofagen bij patiënten 
met erfelijke hemochromatose beinvloed wordt door een verschil in 
percentage aan CD163+ monocyten-macrofagen. 
Ondanks het feit dat het serumijzer en de inhoud aan leverijzer vaak 
verhoogd zijn bij patiënten met chronische hepatitis C, vindt men in de 
meerderheid van deze patiënten geen NTBI in het serum terug. Nochtans 
heeft een minderheid van deze patiënten een verhoogd NTBI gehalte. Verder 
onderzoek zal zich toespitsen op het verband tussen NTBI, het haptoglobine 
fenotype polymorfisme en HII, de invloed van het NTBI gehalte op het 
antwoord na een antivirale behandeling. Tenslotte zal bestudeerd worden of 
de invloed van aderlatingen bij patiënten met een hoog NTBI gehalte het 
antwoord na een antivirale behandeling kunnen beïnvloeden. 
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LIST OF ABBREVIATIONS 
 
ALT :  Alanine aminotransferase 
AST:  Aspartate aminotransferase 
CTL :  Cytotoxic T Lymphocyte 
DCT1 :   Divalent cation transporter 1 
DMT1 :  Divalent metal transporter 1 
E1 :  Envelope protein 1 
E2 :  Envelope protein 2 
EASL :  European Association for the Study of  the Liver 
EDTA :  Ethylene diaminetetraacetic acid 
Hb :  Haemoglobin 
HCV :  Hepatitis C virus 
HFE :  Hemochromatosis gene 
HFE :   Hemochromatosis protein  
HH :  Hereditary hemochromatosis 
HIC:  Hepatic iron content 
HII:  Hepatic iron index 
HLA :  Human major histocompatibility complex 
Hp:  Haptoglobin gene 
Hp:  Haptoglobin protein 
HPLC:  High performance liquid chromatography 
Ireg1:  Iron regulating protein 1 
MHC:   Major histocompatibility complex 
MU:  Million units 
Nramp2:  Natural resistance associated macrophage protein 2 
NTBI:  Non-transferrin-bound iron 
PCR:  Polymerase chain reaction 
Th1:  T helper 1 lymphocyte 
Th2:  T helper 2 lymphocyte 
 
Phenotype (in this work): biochemical characteristics of the different Hp proteins found in 
serum, reflecting differences in the genetics of the Hp protein. 
